

RECOMMENDATIONS FOR THE MANAGEMENT OF MEDICAL COMPLICATIONS IN PATIENTS FOLLOWING ANEURYSMAL SUBARACHNOID HEMORRHAGE

Vesna Vargek Solter¹, Marina Roje-Bedeković¹, Tomislav Breitenfeld¹, Višnja Supanc¹, Arijana Lovrenčić-Huzjan¹, Vesna Šerić¹, Igor Antončić², Silvio Bašić³, Vili Beroš⁴, Ivan Bielen⁵, Silva Butković Soldo⁶, Dragutin Kadojić⁶, Ivo Lušić⁷, Branka Maldini⁸, Anton Marović⁷, Josip Paladino⁹, Zdravka Poljaković¹⁰, Branko Radanović⁶, Marko Radoš¹¹, Krešimir Rotim⁴, Miroslav Vukić⁹, Dijana Zdravec¹², Vanja Bašić Kes¹

¹University Department of Neurology, Sestre milosrdnice University Hospital Center, Zagreb

²University Department of Neurology, Rijeka University Hospital Center, Rijeka

³University Department of Neurology, Dubrava University Hospital, Zagreb

⁴University Department of Neurosurgery, Sestre milosrdnice University Hospital Center, Zagreb,

⁵University Department of Neurology, Sveti Duh University Hospital, Zagreb

⁶University Department of Neurology, Osijek University Hospital Center, Osijek

⁷University Department of Neurology, Split University Hospital Center, Split

⁸University Department of Anesthesiology, Resuscitation and Intensive Medicine, Sestre milosrdnice University Hospital Center, Zagreb

⁹University Department of Neurosurgery, Zagreb University Hospital Center, Zagreb

¹⁰University Department of Neurology, Zagreb University Hospital Center, Zagreb

¹¹University Department of Diagnostic and Interventional Radiology, Zagreb University Hospital Center, Zagreb

¹²University Department of Diagnostic and Interventional Radiology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

SUMMARY – These are evidence based guidelines for the management of medical complications in patients following aneurysmal subarachnoid hemorrhage, developed and endorsed by the Croatian Society of Neurovascular Disorders, Croatian Society of Neurology including Section for Neurocritical Care, Croatian Neurosurgical Society, Croatian Society for Difficult Airway Management and Croatian Medical Association. They consist of recommendations for best monitoring, medical treatment and interventions based on the literature, evaluation of the results of large international clinical trials, and collective experience of the authors.

Key words: *Subarachnoid hemorrhage; Aneurysm; Complications; Medical treatment; Practice guideline*

Subarachnoid hemorrhage (SAH) is a relevant health problem and a significant cause of morbidity and mortality throughout the world. The annual incidence of aneurysmal SAH (aSAH), which varies

widely among populations, perhaps because of genetic differences, competing burden of disease and issues of case ascertainment, is generally accepted to be 9.1 *per* 100 000 *per* year worldwide¹. Because death resulting from aSAH often occurs before hospital admission, the true incidence of aSAH might be even higher². The data also show that the incidence of aSAH increases with age, with a typical average age at onset

Correspondence to: *Marina Roje Bedeković, MD, PhD*, University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska c. 29, HR-10000 Zagreb, Croatia
E-mail: mroje@mef.hr

in adults ≥ 50 years^{1,3}, increases as children get older^{1,4}, is higher in women than in men⁵, with a higher incidence reported in younger men (24–45 years of age), in women between 55 and 85 years and men >85 years of age, and also differs according to race and ethnicity^{6,7}.

The prognosis of aSAH is influenced by multiple non-modifiable factors and by factors that can be influenced by therapeutic interventions and management procedures. The most reliable data on the natural history of ruptured saccular intracranial aneurysms are obtained from the study by Pakarinen *et al.*⁸. Cumulative case fatality rates over time after aSAH are as follows: day 1: 25%–30%; week 1: 40%–45%; first month: 50%–60%; sixth month: 55%–60%; year 1: 65%; and year 5 after SAH: 65%–70%. It is estimated that approximately 12% of patients die before reaching medical attention⁹. If those patients who die before medical attention are included, 43% of all SAH patients die without recovering from the initial bleeding; of those, 74% die within the first 24 hours, 7% within 2–3 days, 12% within 4–7 days, 5% within week 2, 1% within week 3, and 1% later than 3 weeks after the initial SAH⁸. If a ruptured aneurysm is left untreated, about one-third of patients who recover from the initial hemorrhage die because of recurrent bleeding within 6 months after SAH¹⁰. The cumulative risk of rebleeding by 6 months after SAH is 50%, the annual risk of rebleeding decreases to 3% during the next 10 years, while in two-thirds of these late, recurrent bleedings cause death^{11–13}. Despite improvements in surgical and medical treatment, rupture of an aneurysm is still associated with high rates of case fatality (roughly one-third) and severe disability (one-sixth)^{14,15}. However, between 1973 and 2002, the case fatality rate decreased by approximately 17%¹⁶ and the possibility to recover an independent state has increased by 1.5% *per year*¹⁴. Case fatality and functional outcome after SAH are determined by the severity of the initial bleeding^{14,17}, age^{17,18}, aneurysm site¹⁸ and size^{17,18}, history of hypertension^{17,18}, high systolic blood pressure¹⁷, heavy alcohol consumption¹⁹ and cigarette smoking, that has also been reported to increase the risk of delayed cerebral ischemia (DCI)²⁰.

After aneurysm rupture, the possibility of poor outcome rises and is probably determined by multiple independent factors including disease-associated

events, treatment-associated factors and complications associated with prolonged bed rest. As described above, aSAH can have devastating effects on the central nervous system as well as a profound impact on several other organs. The course of the disease can be prolonged and additionally complicated by systemic manifestations affecting cardiovascular, pulmonary and renal function. Due to profound effects of the hemorrhage itself and accompanying complications, aSAH patients are routinely admitted to an intensive care unit (ICU) and are cared for by a multidisciplinary team including neurologists–neurointensivists, neurosurgeons, anesthesiologists and interventional neuroradiologists. The ICU course of aSAH patients ranges from a few days to a few weeks and is frequently accompanied by multiple medical complications²¹, including the following: hydrocephalus, rebleeding, delayed cerebral ischemia from vasospasm, seizures, cardiopulmonary complications and hyponatremia.

There have been few guidelines published for aSAH management^{22–24}, emphasizing mostly risk factors, prevention, natural history and prevention of rebleeding, and recommendations discussing the critical care issues involved in the care of aSAH patients²¹. Since the complex multiorgan pathophysiology of aSAH presents a multitude of clinical challenges which demand attention²¹, the purpose of these Recommendations is to offer an overview and practice guidelines for the management of medical complications in patients following aSAH, being responsible for the outcome and health-related quality of life in patients after aSAH. Recommendations are in accordance with the Recommendations of the Neurocritical Care Society's Multidisciplinary Consensus Conference²¹, Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage for Healthcare Professionals of the American Heart Association/American Stroke Association²², and European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid Hemorrhage²³. Recommendations have been developed based on the literature, evaluation of the results of large international randomized controlled trials and the collective experience of the authors. These Recommendations have been assessed and endorsed by the Croatian Society of Neurovascular Disorders, Croatian Society of Neurology – Section of Neurocritical Care, Croatian Society of Neu-

rosurgery, and Croatian Society for Difficult Airway Management.

These Recommendations are assessing the complications of aSAH. Because of the multiplicity of different complications and low incidence of each, not being high enough to conduct a prospective clinical trial, the superiority of certain procedure over the other was not possible to assess. Most of the complications are managed according to the expert opinion. Therefore, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was preferred for the evaluation of evidence and recommended treatment.

As specified, the quality of the data was assessed and recommendations have been developed using the GRADE system²⁵. The quality of evidence was graded as:

- High = Further research is very unlikely to change our confidence in the estimate effects.
- Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- Very low = Any estimate of effect is very uncertain.

The GRADE system classifies recommendations as strong or weak, according to the balance among benefits, risks, burden and cost, and the quality of evidence. An advantage of GRADE system is that it allows for strong recommendations in the setting of lower quality evidence and thus it is well suited to this situation²⁵. Recommendations were either strong or weak and based primarily on the quality of evidence and translation of the evidence into practice in a specific setting.

Hydrocephalus

Aneurysmal SAH can cause hydrocephalus, defined as a bicaudate index on the computed tomography (CT) scan exceeding the 95th percentile for age, by two mechanisms: obstruction of cerebrospinal fluid (CSF) pathways (i.e. acute, obstructive, noncommunicating type) and blockage of arachnoid granulations by scarring (i.e. chronic, delayed, nonobstructive,

communicating type)²⁶. Acute hydrocephalus occurs in 15% to 87% of patients with aSAH^{27,28}. Chronic shunt-dependent hydrocephalus occurs in 8.9% to 48% of patients with aSAH²⁹⁻³¹.

Acute hydrocephalus may be caused by obstruction of the CSF circulation pathways by interfering with CSF outflow through the sylvian aqueduct, fourth ventricular outlet, basal cisterns and subarachnoid space. CSF production and absorption rates are unaltered³². Intraventricular blood is the strongest determinant for the development of acute hydrocephalus. Other risk factors include bilateral ambient cisternal blood, increased age, vasospasm, use of antifibrinolytic drugs, left ventricular systolic dysfunction, subdural hematoma and seizures³³. Acute hydrocephalus associated with SAH is usually managed by external ventricular drainage or lumbar drainage. External ventricular drainage for patients with aSAH is generally associated with neurological improvement³⁴. About one-third of patients with acute hydrocephalus are asymptomatic and half of the patients with initial hydrocephalus and impairment of consciousness improve spontaneously within 24 hours³⁵. Patients with acute hydrocephalus may be in poor neurological condition immediately after aSAH and have dilated ventricles on CT scan. Such acute hydrocephalus is related to the amount of intraventricular hemorrhage rather than aneurysmal bleeding itself³⁶. Some neurosurgeons prefer not to use ventricular drain in these patients immediately, as half of them will improve spontaneously and there is a risk of rebleeding and infection. The risk of aneurysm rebleeding with external ventricular drainage has been studied in 3 retrospective case series, and the risk of rebleeding was found to be high in one study³⁷, whereas the other 2 studies found no increased risk^{38,39}. Although ventriculostomy increases the risk of rebleeding and meningitis/ventriculitis⁴⁰, the recommended approach is to start immediate external ventricular drainage keeping intracranial pressure between 10 and 20 mm Hg in all of these patients, if there is no other obvious explanation for a reduced level of consciousness, such as massive intracerebral hemorrhage (ICH)⁴¹. Lumbar drainage as a consecutive treatment of external ventricular drainage before shunting for the treatment of aSAH associated hydrocephalus has been reported to be safe in terms of no increase in the risk of re-

bleeding, particularly in patients with spontaneous ICH when the third and fourth ventricles are free of blood, i.e. communicating hydrocephalus. This approach may be considered as an alternative approach to reduce the frequency of permanent shunts, but it is important to pay attention to downward herniation in case of supratentorial swelling and the development of hygroma^{42,43}. The theoretical risk of tissue shift after placement of lumbar drain in patients with severe intracranial hypertension should be considered when deciding which method of cerebrospinal fluid diversion to use, particularly in patients with associated intraparenchymal hematomas. When obstructive hydrocephalus is suspected, an external ventricular drainage should be preferred. Furthermore, preliminary data have also suggested that lumbar drainage is associated with a reduced incidence of vasospasm^{44,45}. Serial lumbar punctures to manage acute aSAH associated hydrocephalus have also been described as safe, but this strategy has only been assessed in small retrospective series^{38,46}.

Only a proportion of patients with aSAH associated acute hydrocephalus develop shunt-dependent chronic hydrocephalus. A number of retrospective series have attempted to identify factors predictive of its development^{29,30,47,48}. A meta-analysis of 5 non-randomized studies with 1718 pooled patients (1336 having undergone clipping and 382 having undergone coiling) found a lower risk of shunt dependency in the clipping group (relative risk 0.74; 95% confidence interval, 0.58-0.94) than in the coiling group ($p < 0.01$)⁴⁸. However, only 1 out of 5 studies showed an independent significant difference⁴⁹. Three other nonrandomized series not included in the meta-analysis showed no significant difference between clipping and coiling in shunt-dependent chronic hydrocephalus^{31,50,51}. Fenestration of lamina terminalis has been suggested to reduce the incidence of shunt-dependent chronic hydrocephalus, yet a meta-analysis of 11 randomized studies with 1973 pooled patients found no significant difference between patients who had and had not undergone fenestration of the lamina terminalis⁵². A nonrandomized study not included in the meta-analysis and not reporting statistical significance compared 95 patients who had undergone aneurysmal clipping, cisternal blood evacuation and lamina terminalis fenestration with 28 comparable, non-blood-cleansed,

endovascular therapy-treated patients and found that shunt-dependent hydrocephalus occurred in 17% of surgical patients *versus* 33% of patients treated with endovascular therapy⁵⁰.

Recommendations for the management of hydrocephalus associated with aSAH

- Aneurysmal SAH-associated acute symptomatic hydrocephalus should be managed by cerebrospinal fluid diversion (external ventricular drainage or lumbar drainage, depending on the clinical scenario) (Moderate Quality Evidence; Strong Recommendation).
- Aneurysmal SAH-associated chronic symptomatic hydrocephalus should be treated with permanent cerebrospinal fluid diversion (Low Quality of Evidence; Strong Recommendation).
- Weaning external ventricular drainage over >24 hours does not appear to be effective in reducing the need for ventricular shunting (Moderate Quality of Evidence; Weak Recommendation).
- Routine fenestration of the lamina terminalis is not useful for reducing the rate of shunt-dependent hydrocephalus and therefore should not be routinely performed (Moderate Quality of Evidence; Weak Recommendation).

Rebleeding

Rebleeding following aSAH is a common event and is associated with very high mortality and poor prognosis for functional recovery in survivors. The risk of rebleeding is maximal in the first 2 to 12 hours, more than one-third of rebleeds occur within 3 hours, and nearly half within 6 hours of symptom onset⁵³, with reported rates of occurrence between 4% and 13.6% within the first 24 hours (that is, during transportation or before the treatment team is able to occlude the aneurysm)⁵⁴, and 5%-10% in the first 72 hours⁵⁵. Early rebleeding is associated with worse outcome than later rebleeding⁵⁶. Patients surviving the first day after the initial aSAH have a cumulative risk of 35%-40% to suffer rebleeding of the aneurysm, with a mortality rate of about 40%. After 4 weeks, the risk of rebleeding decreases to about 3%/year⁵⁷. Factors associated with aneurysm rebleeding include longer time to aneurysm treatment, worse neurologi-

cal status on admission, initial loss of consciousness, previous sentinel headaches, larger aneurysm size and possible systolic blood pressure >160 mm Hg⁵⁸⁻⁶⁰. Genetic factors, although related to the occurrence of intracranial aneurysms, do not appear to be related to an increased incidence of rebleeding⁶¹.

The primary goal of the treatment of aneurysmal SAH is immediate repair of the ruptured aneurysm, in order to close the bleeding source and prevent rebleeding. Some patients either have too high Hunt and Hess Scale (HHS) score for immediate repair or require transport to a center where repair can be performed by experienced team, in order to minimize the serious procedural side effects of repair. Those facts can lead to further delay in repair and increased risk of rebleeding. Among the patients who present in a delayed manner and during the vasospasm window, delayed obliteration of aneurysm is associated with a higher risk of rebleeding⁶². Three interventions are considered that might modulate the risk of rebleeding: blood pressure control, antifibrinolytic therapy, and catheter *versus* CT.

Blood pressure control

There is a general agreement that acute hypertension should be controlled after aSAH and until aneurysm obliteration, but parameters for blood pressure control have not been defined and there are no systematic data that address blood pressure levels in patients with unsecured aneurysms in relation to the risk of rebleeding. Data from observational studies suggest that aggressive treatment of blood pressure may decrease the risk of rebleeding, but at the cost of an increased risk of secondary ischemia⁶³. Recent series do not report rebleeding at systolic blood pressure in the range of 160-200 mm Hg⁶³. It seems reasonable, but without good evidence, to stop any antihypertensive medication that the patients were using and not to treat hypertension unless the blood pressure is extreme. It is not possible to give limits for 'extreme' blood pressure because it differs in different patients according to their age, previous blood pressure, cardiac history, and other factors and limits should be set on an individual basis. The clear consensus is that modest blood pressure elevation (mean arterial pressure <110 mm Hg; systolic blood pressure <160 mm Hg) is not associated with rebleeding and does not re-

quire therapy; extreme hypertension, i.e. if the systolic blood pressure exceeds 180 mm Hg, in patients with an unsecured, recently ruptured aneurysm, should be treated aiming to a modest (e.g., 25%) decrease in the mean arterial pressure; pre-morbid baseline blood pressures should be used to refine targets and hypotension should be avoided²¹.

A variety of titratable medications are available. Nicardipine may give smoother blood pressure control than labetalol⁶⁴ and sodium-nitroprusside⁶⁵, although data showing different clinical outcomes are lacking. Although lowering cerebral perfusion pressure may lead to cerebral ischemia⁶³, a cohort study of neurologically critically ill patients did not find an association between the use of nicardipine and reduced brain oxygen tension⁶⁶. To conclude, between the time of aSAH symptom onset and aneurysm obliteration, blood pressure should be controlled with a titratable agent to balance the risk of stroke, hypertension-related rebleeding, and maintenance of cerebral perfusion pressure.

Antifibrinolytic therapy

Because of the increased risk of intracranial bleeding from thromboprophylaxis by means of low-molecular weight heparins, more often intracranial bleeding complications and no overall influence on outcome or appearance of post-aSAH cerebral infarction^{67,68}, the use of stockings and/or pneumatic devices seems more appropriate in aSAH patients before occlusion of the aneurysm²³. In case that deep vein thrombosis prevention is indicated, low-molecular-weight heparin should be applied not earlier than 12 h after surgical occlusion of the aneurysm and immediately after coiling²³.

Antifibrinolytic therapy has been shown to reduce the incidence of aneurysm rebleeding when there is a delay in aneurysm obliteration. In a Cochrane review including 9 randomized trials of antifibrinolytic drugs in aSAH, antifibrinolytic treatment reduced the risk of rebleeding but did not influence death from all causes or a poor outcome⁶⁹. One referral center instituted a policy of short-term use of aminocaproic acid to prevent rebleeding during patient transfer. It led to a decreased incidence of rebleeding, without increasing the risk of delayed cerebral ischemia and increased risk of deep venous thrombosis but no pulmonary em-

bolism, with no effect on 3-month clinical outcomes⁷⁰. A Swedish trial tested a strategy where tranexamic acid was given as soon as aSAH had been diagnosed in the local hospital (before the patients were transported) and continued until aneurysm occlusion, which was typically performed within 72 hours. It showed again the overall outcome that did not appreciably improve in patients treated with tranexamic acid, despite an impressive reduction in rebleeding⁷¹. If this trial is pooled with the 9 other trials included in the Cochrane review, there is still no effect on overall outcome⁷².

Antifibrinolytic therapy is relatively contraindicated in patients with risk factors for thromboembolic complications (Moderate Quality Evidence; Strong Recommendation) and consequently, patients treated with antifibrinolytic therapy should have close screening for deep venous thrombosis (Moderate Quality Evidence; Strong Recommendation)²¹. For patients with an unavoidable delay in obliteration of aneurysm, a significant risk of rebleeding and no compelling medication contraindications, short term (<72 hours) therapy with tranexamic acid or aminocaproic acid to reduce the risk of early aneurysm rebleeding is reasonable²² (Moderate Quality Evidence; Moderate Recommendation). In accordance with the above, an early, short course of antifibrinolytic therapy prior to early aneurysm repair (begun at diagnosis, continued up to the point at which the aneurysm is secured or at 72 hours post-ictus, whichever is shorter) should be considered²¹ (Low Quality Evidence; Weak Recommendation). Furthermore, delayed (>48 hours after the ictus) or prolonged (>3 days) antifibrinolytic therapy exposes patients to side effects of therapy when the risk of rebleeding is sharply reduced and should be avoided²¹ (High Quality Evidence; Strong Recommendation) and it should be discontinued 2 hours before planned endovascular ablation of the aneurysm²¹ (Very Low Quality Evidence; Weak Recommendation).

Neither aminocaproic acid nor tranexamic acid is approved by the United States Food and Drug Administration (US FDA) or by European Medical Agency (EMA) for the use in European Union, for prevention of aneurysm rebleeding²². There is currently no medical treatment that improves outcome by reducing rebleeding²³ (High Quality Evidence;

Strong Recommendation). Although theoretically recombinant factor VIIa might prevent rebleeding, at this moment there is no evidence to support the use of recombinant factor VIIa outside study protocols in patients with aSAH²³. Further definitive evidence of benefit from antifibrinolytic agents will require additional trials before this therapy can be implemented in clinical practice.

Catheter versus CT angiography

Several individual case reports or case series with poorly defined total number of patients have reported aneurysmal rebleeding with rates as high as 20%-38.5% when digital subtraction angiography (DSA) is undertaken very early (less than 3-6 hours) following aSAH⁷³⁻⁷⁶. The results showed that the figures were much lower (~5%) where a clear denominator was provided to assess the incidence of rebleeding⁷⁴; furthermore, it is unclear whether these instances of rebleeding with DSA actually reflect the risk of the procedure or are simply a manifestation of the high rebleeding rates, known to occur after initial aneurysm rupture; and, finally, there is no satisfactory direct comparison of rebleeding with and without DSA or CT angiography (CTA) within the first 6 hours post aSAH²¹. Given all the above, as well as the fact that CTA is now well established and it seems unlikely that a large study comparing DSA and CTA will ever materialize, it seems unreasonable to conclude that this is a specific risk attributed to ultra early DSA. Based on epidemiological data, choosing CTA over DSA for ultra-early angiography is a reasonable option where both options are available, the technical quality of CTA is good, and an endovascular intervention is not planned at the time of angiography²¹. However, there is no case for delaying investigation, either CTA or DSA, in the setting of aSAH, where the overwhelming aim is to detect and secure a culprit aneurysm²¹.

Recommendations for medical measures to prevent rebleeding after aSAH

- Early aneurysm repair should be undertaken, when possible and reasonable, to prevent rebleeding²¹ (High Quality Evidence; Strong Recommendation).

- If possible, it should be aimed to intervene at least within 72 hours after onset of first symptoms²³ (High Quality Evidence; Strong Recommendation).
- This decision should depend on grading since, according to our experience, patients with worse clinical presentation (HH IV and V) should be individually evaluated and treated as soon as they become medically stable. Otherwise, the risk of treatment outweighs the risk of rerupture.
- Between the time of aSAH symptom onset and aneurysm obliteration, blood pressure should be controlled with a titratable agent to balance the risk of stroke, hypertension-related rebleeding and maintenance of cerebral perfusion pressure²² (High Quality Evidence; Strong Recommendation).
- The magnitude of blood pressure control to reduce the risk of rebleeding has not been established, but a decrease in systolic blood pressure to <160 mm Hg is reasonable (Moderate Quality Evidence; Strong Recommendation).
- Modest elevation in blood pressure (mean blood pressure <110 mm Hg) does not require therapy. Pre-morbid baseline blood pressures should be used to refine targets; hypotension should be avoided²¹ (Low Quality Evidence; Strong Recommendation).
- An early, short course of antifibrinolytic therapy prior to early aneurysm repair (begun at diagnosis; continued up to the point at which the aneurysm is secured or at 72 hours post-ictus, whichever is shorter) should be considered²¹ (Low Quality Evidence; Weak Recommendation).
- Delayed (>48 hours after the ictus) or prolonged (>3 days) antifibrinolytic therapy exposes patients to side effects of therapy when the risk of rebleeding is sharply reduced and should be avoided²¹ (High Quality Evidence; Strong Recommendation).
- Antifibrinolytic therapy is relatively contraindicated in patients with risk factors for thromboembolic complications²¹ (Moderate Quality Evidence; Strong Recommendation).
- Patients treated with antifibrinolytic therapy should have close screening for deep venous thrombosis²¹ (Moderate Quality Evidence; Strong Recommendation).
- When CTA and DSA are both available and CTA is of high technical quality, CTA should be performed preferentially if endovascular intervention is not planned at the time of angiography²¹ (Very Low Quality Evidence; Weak Recommendation).
- There is currently no medical antifibrinolytic treatment that improves outcome by reducing rebleeding²³ (High Quality Evidence; Strong Recommendation).

Delayed Cerebral Ischemia from Vasospasm

Delayed cerebral ischemia from vasospasm is one of the most common causes of death, disability and delayed neurological deterioration following aSAH⁷⁶. Notwithstanding, the definitions used to describe vasospasm and DCI are numerous and not standardized, which makes it difficult to compare results between treatment or intervention trials, and interferes with the development of evidence based guidelines. One of the major contributors to this problem is the inappropriate tendency to combine radiographic evidence of vascular narrowing and clinical findings into a single definition. It is a general agreement that inconsistencies in the use of the terms vasospasm and DCI should be avoided and that standardized definitions are needed²¹.

Vasospasm is a term applied to arterial narrowing after SAH demonstrated by radiographic images or sonography. It is generally accepted that it should only be used as a term describing the findings on diagnostic studies. It is believed to be induced in the areas of thick subarachnoid clot⁷⁸. The putative agent responsible for vasospasm is oxyhemoglobin, but its true etiology and pathogenesis remain to be elucidated⁷⁹. According to current knowledge, the cascade of events culminating in arterial narrowing is initiated when oxyhemoglobin comes in contact with the albuminal side of the vessel events⁸⁰. Most often, the terminal internal carotid artery or the proximal portions of the anterior and middle cerebral arteries are involved. The arterial territory involved, however, is not related to the location of the ruptured aneurysm⁸¹. While changes in vasospasm are commonly observed in the large caliber conveyance arteries, effects on the smaller vessels of the microcirculation, including alterations in blood brain barrier permeability, may be equally important in determining clinical impact.

Such factors may account for the higher incidence of vasospasm as defined by imaging criteria ('radiographic vasospasm') than the rates of neurological dysfunction ('clinical vasospasm')⁸². Vasospasm can result in decreased cerebral blood flow and oxygen delivery, which may produce DCI, a term applied to any neurological deterioration (e.g., hemiparesis, aphasia, altered consciousness) presumed to be related to ischemia, which persists for more than an hour and cannot be explained by other physical abnormalities noted on standard radiographic, electrophysiological or laboratory findings⁷⁸. Neurological deterioration in the context of SAH encompasses clinically detectable neurological deterioration in a SAH patient following initial stabilization, but excludes further SAH due to new bleeding from the ruptured aneurysm. It is also generally agreed that "clinical deterioration due to DCI" should only be used to describe a clinical finding⁷⁸. DCI may occur but neurological deterioration may not be recognized due to poor clinical condition of the patient and/or administration of sedatives. Furthermore, although DCI and vasospasm are often used as surrogate markers of each other and they can both be associated with clinical deterioration and worse outcomes, either one may also be asymptomatic and they can also occur independently²¹. Since recent studies provided evidence that cerebral infarction on neuroimaging had the strongest association with functional outcomes⁸³⁻⁸⁵, it has been recommended recently by a multidisciplinary research group that SAH clinical trials should only use cerebral infarction and functional outcome as the primary outcome measures, whereas clinical deterioration due to DCI and vasospasm on angiography or TCD should only be secondary outcome measures²¹.

Monitoring strategies for delayed neurological deterioration, delayed cerebral ischemia and vasospasm

Knowing that DCI is one of the most common causes of delayed neurological deterioration and the major cause of secondary morbidity that is potentially treatable and reversible, early detection of impaired cerebral perfusion and early intervention to detect and reverse ischemia before the occurrence of permanent infarction is the goal of monitoring for DCI after aSAH. Furthermore, it is considered a high-priority

topic because the choice of monitoring strongly influences the specific triggers used for further hemodynamic or endovascular intervention to treat vasospasm and DCI. The highest risk period for DCI occurs 3-14 days after aSAH and higher risk patients are those with larger amounts of SAH and poorer clinical grade²¹.

Monitoring strategies and tools for DCI in SAH are divided into three basic categories: clinical, radiographic and physiological²¹, the last two being commonly used to identify arterial narrowing and perfusion abnormalities or reduced brain oxygenation. These different tools have advantages and disadvantages.

Clinical monitoring for DCI consists of repeated neurological assessments to identify new neurological deficits that are attributable to ischemia or infarction. Two studies found that CT scans identified asymptomatic infarction in 10%-20% of patients with clinically unrecognized infarcts, more common in patients in coma^{86,87}. A study using magnetic resonance imaging (MRI) found clinically unrecognized infarcts in 23% of patients⁸⁸. The results of the studies clearly showed that not all ischemic events are detected on clinical examinations and it is generally thought that the utility of clinical examination in detecting reversible ischemia is good in good-grade patients and less reliable in poor-grade patients who are obtunded or comatose. Notwithstanding, there is a strong consensus that clinical examination is an important first assessment point in patients with aSAH; that triggers for further monitoring and intervention may differ depending on the clinical status of the patient; and that clinical examination alone is an insufficient monitoring paradigm for detection of DCI, especially in poor-grade patients²¹. Furthermore, there is a general consensus that additional radiographic and/or physiological monitoring should be routinely employed in the monitoring of aSAH patients for DCI and should be performed during the DCI at risk period, even in the absence of clinical evidence of DCI or prior to its occurrence²¹.

Radiographic monitoring modalities include conventional digital subtraction angiography (DSA), CT (CT angiography, CTA and CT perfusion imaging, CTP) and MRI. DSA is considered gold standard for detection of arterial narrowing and thus is a com-

monly used radiographic method to define vasospasm, with a limitation of not being able to assess the adequacy of perfusion to meet metabolic demands of the tissue. On the other hand, CTA is found to be highly correlated with DSA findings of large artery narrowing, 87%-95% specific for angiographic vasospasm compared with DSA and with high specificity and negative predictive value (NPV) of 95%-99%, suggesting that it could be used as a screening tool to limit the use of DSA, but at the same time tends to overestimate the degree of stenosis^{89,90}. CTP does provide some measure of tissue perfusion, which may enhance the predictive value of multi-modality CT for DCI monitoring. Its finding of delayed mean transit time >6.4 s in conjunction with arterial narrowing on CTA is found to be more accurate in predicting the need of endovascular intervention for vasospasm^{91,92}, but it does not currently evaluate the posterior fossa well. Considering MRI as a possible DCI monitoring tool at this time, it would require further trials for adequate and satisfactory data. Overall, according to radiographic monitoring strategy for DCI in aSAH, concerning the emerging concerns regarding radiation toxicity, an institutional protocol that balances DCI detection with attempts to minimize radiation exposure is encouraged.

Physiological monitoring modalities are the third basic category among the monitoring strategies and tools for DCI in aSAH, which include transcranial Doppler ultrasonography (TCD), electroencephalography (EEG), brain tissue oxygen monitoring, cerebral microdialysis, thermal diffusion cerebral blood flow (TD-CBF) monitoring and near-infrared spectroscopy.

Transcranial Doppler ultrasonography has long been used for monitoring patients with aSAH and has been more extensively studied in comparison with DSA. Although studies of TCD diagnostic accuracy for detection of vasospasm and DCI vary widely with regard to sensitivity and specificity^{93,94}, it is generally considered that TCD has a fairly high specificity but only moderate sensitivity compared with DSA^{93,94}. Differentiation of elevated TCD velocities secondary to vasospasm *versus* other causes in monitoring patients with aSAH is crucial. It can be accomplished by measuring velocities in the cervical internal carotid artery (ICA) in addition to the intracerebral vessels,

creating ratios for clinical use that aim to overcome the confounding effects of systemic hemodynamic factors, such as changes in cardiac output or blood pressure. TCD velocities have been used to create several clinically relevant predictive indices, including the Lindegaard ratio (ratio of middle cerebral artery (MCA) TCD velocity to ipsilateral internal carotid artery (ICA) TCD velocity), that is especially useful for vasospasm diagnosis. A V_{MCA}/V_{ICA} ratio >3 is suggestive of cerebral vasospasm⁹⁵. A similar velocity ratio profile between the basilar and extracranial vertebral arteries can be used to assess for basilar vasospasm⁹⁶. A 2001 meta-analysis reported that, for MCA vasospasm, overall TCD specificity was 99% and sensitivity 67%, with a positive predictive value (PPV) of 97% and NPV of 78%. For the anterior cerebral artery (ACA), ICA, posterior circulation and examinations of the distal cerebral microvasculature, TCD values were significantly less sensitive and specific⁹⁷. A consensus statement in 2004 underscored these results, supporting the conclusion that TCD is a reliable predictor for the absence of angiographic vasospasm (high NPV) at flow velocities <120 cm/s and for the presence of angiographic vasospasm (high PPV) at flow velocities >200 cm/s in the MCA territory. According to the mentioned consensus, flow velocities below 120 cm/s (absence), >200 cm/s (presence), MCA/ICA ratio >6 (presence) or rapidly increasing velocities over several days (high risk) are commonly considered thresholds^{94,98}. Velocity measurements between 120 cm/s and 200 cm/s may require further technical maneuvers (manual carotid compression)⁹⁹ or additional clinical information to improve diagnostic accuracy. Moreover, intermediate TCD values generally do not reliably correlate with angiographic vasospasm¹⁰⁰. Clinically, trends in TCD values or interval changes from prior readings are often more informative than absolute values⁸². Daily monitoring of changes in TCD values can speak in favor of development of vasospasm¹⁰⁰. Therefore, TCD on days 2-5 can detect the development of vasospasm days before it can become clinically apparent, and this information can be used by intensivists to step up with hemodynamic management of these patients. On days 5-12, TCD can detect progression to the severe phase of spasm when development of the delayed ischemic deficit due to perfusion failure through the residual lumen is the

greatest. This information can help planning interventions (angiography, nicardipine infusion). On days 12 to the end of ICU stay, TCD can document spasm resolution after treatment or intervention, sustainability of vessel potency, and infrequent cases of late or rebound vasospasm development at the end of the second or into the third week after aSAH. In conclusion, due to the absence of radiation risk, relatively low cost and ease/rapidity of bedside administration, TCD measurements are practical for serially monitoring the progression of cerebral vasospasm. The technique is limited by the lack of high-resolution anatomic detail, and its accuracy and utility are highly operator-dependent and patient movement-dependent. In addition, aberrant vessel course, aneurysm clip artifacts and suboptimal insonation windows can inhibit the detection of pathological velocities^{82,101}.

Brain tissue oxygen (PbtO₂) monitoring and cerebral microdialysis (CMD) are directly measuring tissue oxygen delivery and metabolism, providing, rather than direct correlation, information complementary to that from radiographic studies. Their role in measuring these physiological parameters in monitoring patients with aSAH has been described in several observational studies^{102,103}. However, no studies examined the effectiveness of interventions based on these monitoring tools in preventing or reversing DCI. Regarding the role of EEG in monitoring patients with SAH, findings of reduced alpha variability have been indicative of DCI, but no interventional trials examined EEG-directed DCI treatment¹⁰⁴. Altogether, EEG, PbtO₂ monitoring and CMD may all be useful physiological monitors for DCI detection, but the relative value of these monitors individually *versus* as part of a multi-modality monitoring strategy is not known (Low Quality Evidence; Weak Recommendation)²¹.

To conclude, there is a strong consensus that clinical examination is an important first assessment point in patients with aSAH, while triggers for further monitoring and intervention may differ depending on the clinical status of the patient. Furthermore, there is also great concern that clinical examination alone was an insufficient monitoring paradigm for detection of DCI, especially in poor-grade patients, leading to a consensus that additional radiographic and/or physiological monitoring should be routinely employed in

the monitoring of aSAH patients, performed during the DCI at risk time period, even in the absence of clinical evidence of DCI or prior to its occurrence²¹. Based on the past knowledge and clinical experience, the following can be recommended:

- a) Low Risk Good-Grade aSAH Patients – the primary monitoring tool is repeated clinical evaluation, supplemented by monitoring with regular daily TCD. In case of the development of a new focal deficit, a change in the level of consciousness not clearly attributable to another cause, or an increase in TCD velocities/Lindgaard ratio should prompt additional investigations (CTA or DSA) that seek to detect or monitor the evolution of arterial narrowing and document the presence of perfusion deficits (CTP) that results from such narrowing. Where the selected investigation cannot be obtained emergently, within 1-2 hours, depending on the clinical situation, medical therapy for DCI should be initiated while awaiting imaging²¹.
- b) Good-Grade SAH Patients at High Risk of Vasospasm and/or DCI – patients with a high Fisher grade and/or arterial narrowing demonstrated with DSA/CTA at the time of initial presentation may benefit from monitoring with these techniques in the absence of detectable clinical consequences. The development of new deficits and/or changes in sensorium will often directly trigger therapeutic interventions. In case of substantial clinical uncertainty whether the change in clinical status is actually due to DCI; an endovascular intervention is being considered; and/or the risks of therapy are particularly high (e.g., blood pressure elevation in a patient with significant ischemic heart disease), repeating CTA+CTP should be performed. Regarding the radiation burden and renal impairment, in case of screening for vasospasm or DCI the risk/benefit ratio is considered more favorable²¹.
- c) Sedated or Poor-Grade SAH Patients – clinical examination may be less useful as a monitoring tool in this setting but should still be regularly undertaken, since a change from baseline provides an indication for further investigation or treatment. A clinical suspicion of vasospasm or DCI in these SAH patients will be triggered by a change in TCD parameters, EEG, invasive cerebral moni-

toring, or by the detection of vasospasm or perfusion deficits on routine screening CTA/CTP or DSA. Where the clinical suspicion of DCI is based on a non-imaging tool, it is prudent to confirm the diagnosis using CTA+CTP or DSA. It is reasonable to initiate therapy without further investigation in patients where screening using CTA or DSA has already established vasospasm and the clinical picture is consistent and in poor-grade patients where a perfusion deficit has been demonstrated on screening CTP, unless the deficit coincides with an established infarction²¹.

Considering thresholds for cessation of therapy for DCI, in good-grade patients clinical assessment combined with cautious staged de-escalation of therapy provides the best basis for management decisions, whereas in poor-grade patients, this approach may need to be supplemented by investigations that include TCD trends of vasospasm, continuous EEG monitoring, PbtO₂, and/or microdialysis. In case when DCI has resulted in established infarction, it may be appropriate to withdraw therapy because it has been unsuccessful. It is important to emphasize that it is unwise to base treatment decisions (initiation, titration or withdrawal) on an individual measurement provided by any single monitoring modality or monitoring device (technical artifact, inter-center variability), especially knowing that while some physiological thresholds may be associated with outcome, there is no clear evidence that correction of the monitored variable actually improves outcome. It is prudent to integrate data from all available sources with the clinical picture to help make management decisions. In case of the development of new neurological deficit with a strong likelihood of being due to ischemia and other potential causes were unlikely or had been excluded, most centers would initiate therapy. The threshold values from TCD and other monitoring devices provide additional information that underpins initiation of therapy. Some therapies, including hypertension and optimization of hemoglobin levels, may be initiated while awaiting confirmatory investigations. On the other hand, other interventions used in DCI, such as endovascular therapy, require angiography for initiation and in these instances confirmation of the diagnosis of vasospasm as a cause of DCI will automatically precede therapy²¹. Because of all the above

mentioned challenges in monitoring aSAH patients, there is, however, a strong consensus that monitoring for neurological deterioration and specifically DCI should take place in an environment with substantial multidisciplinary expertise in the management of aSAH (hospital and intensive care unit), with adequate expertise to implement and interpret monitoring tools, where additional monitoring and treatment can be rapidly implemented when needed^{21,105} (Very Low Quality Evidence; Strong recommendation).

Management of Cerebral Vasospasm and DCI after aSAH

Although the pathways leading to arterial narrowing have been in focus of extensive basic research, no effective preventive therapy has been developed to date. Probably, the reason for this stems in part from the fact that the vasospasm occurs at multiple levels in the arterial and arteriolar circulation. It is known that large artery narrowing seen in angiographically visible vessels only results in ischemic neurological symptoms in 50% of patients. Although there is a correlation between the severity of large artery spasm and symptomatic ischemia, there are patients with severe large artery spasm who never become symptomatic and other with modest spasm who not only develop symptoms but go on to develop infarction⁷⁸. Probably many factors contribute to the development of ischemia and infarction, including but not limited to distal microcirculatory failure, poor collateral anatomy, and genetic or physiological variations in cellular ischemic tolerance^{106,107}.

The management of aSAH-induced vasospasm is complex. Currently, the strongest evidence supports the use of prophylactic oral nimodipine and maintenance of euvoolemia and initiation of hemodynamic augmentation therapy (triple-H therapy) for patients with cerebral vasospasm and/or endovascular therapy with vasodilators and angioplasty balloons¹⁰⁸.

As for nimodipine, the results of a recent comprehensive meta-analysis have confirmed improved neurological outcomes by preventing processes other than large-vessels narrowing and should be administered to all patients with aSAH (High Quality Evidence; Strong Recommendation)¹⁰⁹. It should be noted that nimodipine has been shown to improve neurological outcomes by decreasing the incidence of cere-

bral ischemia¹¹⁰, but not cerebral vasospasm. It has been postulated that the nimodipine beneficial role may be the result of a more complex neuroprotective mechanism of action than that of its vasodilatory effect¹¹¹. Although the risk reduction for 'poor outcome' is statistically robust, it depends mainly on a single large trial¹¹² and therefore the benefits of nimodipine cannot be regarded as being beyond all reasonable doubt²³. The practical implication is that the regimen in the dominant nimodipine trial (60 mg orally every 4 h for 3 weeks) is currently regarded as the standard treatment in patients with aSAH. If the patient is unable to swallow, the nimodipine tablets should be coarse-grained crushed and washed down a nasogastric tube with normal saline within minutes²³. Intravenous administration of calcium antagonists is advocated by the manufacturer, but besides the fact that it is more expensive, there is no evidence to support this and cannot be recommended for routine practice on the basis of current evidence¹¹³. The value of other calcium antagonists, whether administered orally or intravenously, remains uncertain²².

With regard to blood volume, maintenance of euvolemia and normal circulating blood volume is recommended to prevent DCI (High Quality Evidence; Strong Recommendation)²¹. When DCI is diagnosed, the initial treatment is the induction of hemodynamic augmentation to improve cerebral perfusion. Traditionally, hemodynamic augmentation has consisted of hemodilution, hypervolemia and hypertensive therapy (triple-H therapy). Although no randomized trial of this intervention has been performed, the rapid improvement of many patients with this therapy and their worsening when it is stopped prematurely are a convincing proof of efficacy. The exact mechanism of benefit is unclear²². In some patients, increased mean arterial pressures may increase cerebral blood flow in the setting of autoregulatory dysfunction, whereas in others, there may be some direct transluminal pressure effect that leads to arterial dilation¹¹⁰. However, the existent literature provides only level B evidence regarding the utilization of triple-H therapy in the management of patients suffering from aSAH¹¹⁴. Recently, MacDonald *et al.* have reported their experience from employing continuous milrinone infusion instead of triple-H therapy. They found that milrinone regimen required less invasive monitoring and

resources than triple-H therapy, while its hemodynamic effect was comparable to that of the triple-H therapy¹¹⁵. Further large-scale clinical trials are necessary for validating their observations. Accumulating literature has shifted the focus from this triple-H therapy to the maintenance of euvolemia and induced hypertension¹¹⁶. Induction of hypertension is recommended for DCI unless blood pressure is elevated at baseline or cardiac status precludes it²³ (High Quality Evidence; Strong Recommendation). The data show that both prophylactic angioplasty of the basal cerebral arteries and antiplatelet prophylaxis are ineffective in reducing morbidity¹¹⁷⁻¹¹⁹. Consequently, prophylactic hypervolemia or balloon angioplasty before the development of angiographic spasm is not recommended²³ (Moderate Quality Evidence; Strong Recommendation); cerebral angioplasty and/or selective intra-arterial vasodilator therapy is reasonable in patients with symptomatic cerebral vasospasm, particularly those who are not rapidly responding to hypertensive therapy (Moderate Quality Evidence; Strong recommendation)²².

With regard to the value of the lumbar drainage after SAH, the data from one case-control study showed a markedly reduced risk of clinically evident vasospasm and its sequels, shortened hospital stay and improved outcome. The beneficial effect is probably mediated through the removal of spasmogens that exist in the CSF, but a randomized clinical trial is warranted and ongoing phase III trial has been designed to test its influence on outcome¹²⁰. The data from a meta-analysis of 5 randomized, controlled trials suggested a benefit from intrathecal thrombolytic infusions following aSAH but further standardization of techniques and evaluation in a larger, more rigorous randomized controlled trial is required¹²¹. The effect of intraventricular fibrinolysis on clinical outcome and mortality of aSAH patients is currently being investigated in a large-scale phase III clinical trial¹²².

The administration of the endothelin-1 antagonist, clazosentan, has been shown to be associated with a dose-dependent reduction in the incidence of angiographic vasospasm in a phase II b trial¹²³, but proven to cause no significant improvement in the clinical outcome of patients with aSAH¹¹⁶.

Significant interest has been arisen by the employment of magnesium as a vasodilatory agent for

preventing and/or reversing cerebral vasospasm. Certainly, the use of magnesium has potential benefits in the setting of aSAH, with the minimal risk of severe adverse or side effects such as hypotension, hypocalcemia or bradycardia. Magnesium reduced the frequency of DCI in a dose-dependant fashion¹²⁴. Results of the Mash-2 (Magnesium for Aneurysmal Subarachnoid Hemorrhage) trial revealed that treatment with magnesium did not improve outcome and was not superior to placebo in reducing poor outcome in SAH patients¹²⁵. The potential role of magnesium in relieving persistent SAH-associated headache needs to be explored in the future. Based on the currently published data, the systemic administration of magnesium cannot be generally recommended. Magnesium sulfate is a promising agent but more evidence is needed before definitive conclusions can be drawn¹²⁶.

In regard to the employment of statins in the management of vasospasm, the currently available data have shown that in the majority of cases there is a definite vasodilatory effect on the cerebral vasculature¹²⁷⁻¹³¹. Results of the STASH (Simvastatin in Aneurysmal Subarachnoid Hemorrhage) trial are expected to clarify the exact effect of statins on the clinical outcome of patients with aSAH.

It has been postulated that other pathophysiological mechanisms than vasospasm may contribute to post-aSAH morbidity and mortality. Inflammatory mechanisms, endothelial apoptosis, cortical spreading depolarization, microthrombosis and lipid peroxidation have been implicated in the pathogenesis of delayed ischemic events¹³²⁻¹³⁵. Other agents with a potential benefit in preventing and/or treating post-aSAH vasospasm and DCI include nitric oxide promoters, free radical scavengers, thromboxane inhibitors, thrombolysis, anti-inflammatory agents and neuroprotectants. Although promising data begin to emerge for several treatments, few prospective randomized clinical trials are presently available. Additionally, future investigational efforts will need to resolve discrepant definitions and outcome measures for cerebral vasospasm in order to permit adequate study comparisons. Until then, definitive recommendations cannot be made regarding the safety and efficacy of each of these therapeutic strategies and medical management practices will continue to be implemented in a wide-ranging manner¹⁰⁸.

Recommendations for prevention of delayed ischemic deficit

- Monitoring for neurological deterioration and specifically DCI should take place in an environment with substantial multidisciplinary expertise in the management of aSAH²¹ (Moderate Quality Evidence; Strong Recommendation). Patients at a high risk of DCI should be closely monitored throughout the at risk period, which is best accomplished in an ICU setting where additional monitoring and treatment can be rapidly implemented²¹ (Very Low Quality Evidence; Strong Recommendation).
- Nimodipine should be administered orally (60 mg/4 h) to all patients with aSAH for a period of 21 days to prevent delayed ischemic events²¹⁻²³ (High Quality Evidence; Strong Recommendation).
- Maintenance of euvolemia and normal circulating blood volume is recommended to prevent delayed cerebral ischemia²² (Moderate Quality Evidence; Strong Recommendation).
- Prophylactic hypervolemia or balloon angioplasty before the development of angiographic spasm is not recommended²² (Moderate Quality Evidence; Strong Recommendation).
- Imaging of vascular anatomy and/or perfusion can be used to confirm the diagnosis of DCI in monitored good-grade patients who show a change in neurological examination or TCD variables²¹ (High Quality Evidence; Strong Recommendation).
- A strategy for detection and confirmation of DCI should be employed. This should first and foremost involve frequent repeat neurological assessment by qualified providers. Intermittent screening or more continuous monitoring methods may additionally be used²¹.
- TCD is reasonable to monitor for the development of arterial vasospasm (Moderate Quality Evidence; Strong Recommendation)²¹⁻²³. Thresholds of mean blood flow velocities <120 cm/s for absence and >200 cm/s and/or MCA/ICA ratio >6 for presence are reasonable²¹ (Moderate Quality Evidence; Strong Recommendation).

- DSA is gold standard for detection of large artery vasospasm²¹ (High Quality Evidence; Strong Recommendation).
- High quality CTA can be used on screening for vasospasm and due to its high specificity may reduce the need of DSA studies²¹ (Low Quality Evidence; Weak Recommendation)²¹.
- Perfusion imaging with CT or MRI can be useful to identify regions of potential brain ischemia²² (Moderate Quality Evidence; Strong Recommendation).
- In high risk patients who have a clinical picture strongly suggestive of DCI and in whom elective screening CTA or DSA has already demonstrated vasospasm/DCI, it is reasonable to initiate medical therapy without further investigation²¹ (Moderate Quality Evidence; Strong Recommendation).
- In patients with clinical uncertainty regarding the cause of neurological deterioration, DSA is indicated if an endovascular intervention is planned²¹ (Moderate Quality Evidence; Strong Recommendation).
- In sedated or poor-grade patients, clinical deterioration may be difficult to assess, and TCD, continuous EEG, PbtO₂ monitoring and/or CMD are options for monitoring for vasospasm and DCI²¹ (Low Quality Evidence; Weak Recommendation).
- Induction of hypertension is recommended for patients with DCI unless blood pressure is elevated at baseline or cardiac status precludes it²² (Moderate Quality Evidence; Strong Recommendation).
- The choice of vasopressor should be based on other pharmacological properties of the agents²¹ (e.g., inotropy, tachycardia) (Moderate Quality Evidence; Strong Recommendation).
- Blood pressure augmentation should progress in a stepwise fashion with assessment of neurological function at each mean arterial pressure (MAP) level to determine if a higher blood pressure target is appropriate²¹ (Poor Quality Evidence; Strong Recommendation).
- If nimodipine administration results in hypotension, then dosing intervals should be changed to more frequent lower doses. If hypotension continues to occur, then nimodipine may be discontinued²¹ (Low Quality Evidence; Strong Recommendation).
- If patients with DCI do not improve with blood pressure augmentation, a trial of inotropic therapy may be considered²¹ (Low Quality Evidence; Strong Recommendation). Inotropes with prominent β -2 agonist properties (e.g., dobutamine) may lower MAP and require increases in vasopressor dosage²¹ (High Quality Evidence; Strong Recommendation).
- Cerebral angioplasty and/or selective intra-arterial vasodilator therapy is reasonable in patients with symptomatic cerebral vasospasm, particularly those who are not rapidly responding to hypertensive therapy²² (Moderate Quality Evidence; Strong Recommendation).
- Hemodilution in an attempt to improve rheology should not be undertaken except for cases of erythrocythemia²¹ (Moderate Quality Evidence; Strong Recommendation).
- If the aneurysm thought to have ruptured is unsecured when the patient develops DCI, cautious blood pressure elevation to improve perfusion might be attempted, weighing the potential risks and benefits²¹ (Weak Quality Evidence; Strong Recommendation).
- Unsecured aneurysms which are not thought to be responsible for the acute SAH should not influence hemodynamic management²¹ (Moderate Quality Evidence; Strong Recommendation).
- Magnesium sulfate is not recommended for the prevention of DCI²³ (High Quality Evidence; Strong Recommendation).
- Statins are under study²³.

Seizures

Retrospective studies have identified several risk factors for the development of early seizures associated with aSAH, including aneurysm in the MCA¹³⁶, thickness of a aSAH clot¹³⁷, associated intracerebral hematoma¹³⁸⁻¹⁴⁰, rebleeding¹³⁷, infarction¹⁴¹, poor neurological grade¹³⁷, history of hypertension¹⁴² and surgical aneurysm repair in patients >65 years of age¹³⁷. Abnormal movements that may appear seizure-like

are common at the onset of aSAH (as many as 26%) but it is usually unclear whether this is a true seizure or represents posturing at the time of aneurysm rupture^{138,143}. The incidence, future implications and management of seizures associated with aSAH are controversial. Clinical seizures are uncommon after the initial aneurysm rupture, occurring in 1%-7% of patients, and when they occur in patients with an unsecured aneurysm, they are often the manifestation of aneurysmal re-rupture^{144,145}. At present, no randomized, controlled trials are available to guide decisions on prophylaxis or treatment of seizures. The mode of treatment for patients with ruptured aneurysms also appears to influence the subsequent development of seizures²². Results of the studies have demonstrated that patients treated by endovascular coiling showed a significantly lower incidence of seizures^{144,146}. Although high-quality evidence for routine anticonvulsant use in aSAH patients without seizures is lacking, short-term prophylactic antiepileptic therapy is still commonly used in patients with aSAH^{137,143}, based on the argument that seizures in acutely ill patients with aSAH could lead to additional injury or rebleeding from an unsecured aneurysm. Recent studies have suggested that prophylactic anticonvulsant therapy with phenytoin may worsen outcome¹⁴⁷, whereas the impact of other anticonvulsant medication is less clear¹⁴⁸. Also, in patients with no history of seizure, a short course (72 h) of anticonvulsant prophylaxis seems as effective as a more prolonged course in preventing seizures¹⁴⁹. On the other hand, the results from one large single-institution study in which anticonvulsants were used routinely showed adverse drug effects in 23% of patients¹³⁷, whereas another single-center retrospective study found the use of prophylactic phenytoin to be independently associated with worse cognitive outcome at 3 months after aSAH¹⁴⁷. Furthermore, data pooled from the trials of the impact of other therapies also suggest worse outcome in those treated with anticonvulsants. The use of anticonvulsants was also associated with vasospasm, DCI and fever, which suggests that there may have been a bias in those who were treated with antiepileptic drugs¹⁴⁸. Likewise, although hampered by limitations such as a small number of patients and anticonvulsant levels not routinely monitored, retrospective studies failed to demonstrate benefit from the use of prophylactic anticonvulsant

after aSAH^{150,151}. Inclusive, it is recommended that any purported benefit of routine anticonvulsant use in aSAH must be tempered by a consideration of the potential risks of use²². However, in case of a certain subgroup of patients, such as elderly patients undergoing craniotomy that have a higher seizure risk, a short course (3-7 days) of anticonvulsant prophylaxis might still be considered in some situations, especially if an agent other than phenytoin is used^{21,152}. There is also agreement that patients who suffer clear clinical seizure after the period of aneurysmal rupture should be treated with anticonvulsants, but that if seizures do not recur, these anticonvulsants should be discontinued after 3-6 months. Contrary, there is no agreement whether an EEG should be performed at that time and, if so, whether seizure-free patients with an epileptic focus should be continued on anticonvulsants²¹.

The association between seizures and functional outcome still remains unclear. Some studies have reported no impact on outcome^{137,143}, whereas others found seizures to be independently associated with worse outcome¹⁵³. Nonconvulsive status epilepticus has been found to be a strong predictor of a poor outcome^{154,155}. Concerning the treatment of nonconvulsive seizures that may be detected on continuous EEG in 10%-20% of comatose aSAH patients that are proved to have worse outcome, the impact of successful treatment as well as the influence of anticonvulsant prophylaxis on the occurrence of nonconvulsive seizures have not been studied. There is a consensus that continuous EEG is underutilized in poor-grade aSAH patients, but it is not clear whether nonconvulsive seizures represent a marker of disease severity or a target for treatment. There is general agreement that one or perhaps two anticonvulsants should be used to attempt to treat nonconvulsive seizures identified on continuous EEG, but there is disagreement whether or not to pursue more aggressive means such as benzodiazepine or barbiturate infusions if initial measures were unsuccessful²¹.

Recommendations for medical management of seizures associated with aSAH

- There is no evidence that supports the prophylactic use of antiepileptic drugs (Very Low Quality Evidence; Weak Recommendation).

- Antiepileptic treatment should be administered in patients with clinically apparent seizures²³.
- In patients who suffer a seizure after presentation, anticonvulsants should be introduced and discontinued after two-year seizure-free period, as defined by local practice²¹ (Low Quality Evidence; Weak Recommendation).
- Continuous EEG monitoring should be considered in patients with poor-grade aSAH who fail to improve or who have neurological deterioration of undetermined etiology; in patients who presented with seizure as the initial symptom of SAH; in patients with a prolonged post-ictal disturbance of consciousness; and in patients with suspicion of nonconvulsive status epilepticus²¹ (Low Quality Evidence; Strong Recommendation).
- The routine long-term use of anticonvulsants is not recommended (Moderate Quality Evidence; Weak Recommendation), but may be considered for patients with known risk factors for delayed seizure disorder, such as prior seizure, intracerebral hematoma, intractable hypertension, infarction or aneurysm at the middle cerebral artery, and for patients with severe epileptiform changes as shown during control EEG monitoring²² (Moderate Quality Evidence; Weak Recommendation).

Cardiopulmonary Complications

Cardiac dysfunction occurs in a significant number of aSAH patients. Neurogenic sympathetic hyperactivity, as well as increased levels of systemic catecholamines, has been implicated in aSAH-associated cardiac dysfunction. Cardiac dysfunction after aSAH is often referred to as 'neurogenic stress cardiomyopathy'¹⁵⁶ and has been attributed to the clinical syndrome of chest pain, dyspnea, hypoxemia and cardiogenic shock with pulmonary edema and elevated cardiac markers occurring within hours of SAH. This syndrome has a wide spectrum of severity and it may contribute to sudden death in 12% of patients. The manifestations are usually transient, lasting for 1-3 days, after which myocardial function returns to normal. The management should be focused on supportive care that balances cardiac needs with the neurological goals¹⁵⁷.

Arrhythmias occur in as many as 90% of patients and are most prevalent in the first 48 hours following aSAH. They most commonly include premature ventricular complexes, bradyarrhythmias and supraventricular tachycardia. Serious cardiac arrhythmias, most often atrial fibrillation or flutter, have been described in approximately 5% of patients¹⁵⁸. Clinically significant arrhythmias after aSAH are associated with a high mortality rate and serious cardiac and neurological comorbidity¹⁵⁹.

Electrocardiographic changes occur during the acute stage in 50% to 100% of aSAH patients^{160,161}. The most common abnormalities are nonspecific ST deviations, T-wave inversion and prolonged QT interval. These ECG changes have no clinical or prognostic consequence. Elevated troponin is found in approximately 20% of aSAH cases and is associated with an increased risk of hypotension, pulmonary edema, left ventricular dysfunction and DCI¹⁶²⁻¹⁶⁴. Patients with an abnormal ECG on admission should undergo close cardiac monitoring. The presence of rhythm disturbances should prompt aggressive measures to treat myocardial infarction, maintain normal cardiac rhythm, and minimize the presence of autonomic stress¹⁵⁹. The cardiac injury that is found in up to 15% of aSAH patients is probably caused by the massive release of catecholamines¹⁶⁵.

Transient left ventricular dysfunction with an akinetic or dyskinetic apex has also been described in aSAH patients without significant coronary heart disease^{166,167}. This phenomenon known as *Takotsubo cardiomyopathy* or transient left ventricular apical ballooning¹⁶⁸ is caused by severe physical (e.g., SAH) or emotional stress. More than 95% of patients that experienced this stress-induced cardiomyopathy are female¹⁶⁹. Plasma catecholamine concentrations in these patients are remarkably higher than in patients presenting with myocardial infarction. A possible explanation of this cardiomyopathy is ischemia caused by coronary spasm¹⁶⁹.

Symptomatic pulmonary complications that are associated with worse clinical grade aSAH and higher mortality occur in over 20% of patients after aSAH^{170,171}. Aneurysmal SAH patients may develop cardiac or neurogenic pulmonary edema¹⁷², acute lung injury or acute respiratory distress syndrome. The excessive release of catecholamines (epinephrine/nor-

epinephrine) or cardiac failure has been suggested as the principal cause of pulmonary complications^{172,173}. It is also suggested that patients who experience pulmonary complications after aSAH have a higher incidence of symptomatic vasospasm than do patients without pulmonary complications. This most likely reflects a failure to maintain aggressive hypervolemic and hyperdynamic therapy in patients with compromised pulmonary function, as well as the possible precipitation of congestive heart failure by hypervolemic therapy in patients with preexisting delayed ischemic neurological deficit¹⁷⁴.

Pulmonary complications challenge medical management of patients who have sustained aSAH. Cardiopulmonary issues are worsened in the event of hypervolemia, thus the goal of therapy should be euvolemia. In general, cardiopulmonary abnormalities are more common in patients who later develop DCI and have worse outcomes¹⁷⁵. They frequently complicate management by increasing procedural risk and exacerbate brain oxygen delivery by lowering perfusion pressure and arterial oxygenation saturation. The management of these complications is heterogeneous, may vary based on the patient's clinical status, and in the setting of vasospasm and interventions should reflect current best medical practice²¹.

Recommendations for monitoring and medical treatment of cardiopulmonary complications in aSAH patients

- Baseline cardiac assessment with serial enzymes, electrocardiography and echocardiography is recommended, especially in patients with evidence for myocardial dysfunction²¹ (Low Quality Evidence; Strong Recommendation).
- Monitoring of cardiac output may be useful in patients with evidence of hemodynamic instability or myocardial infarction²¹ (Low Quality Evidence; Strong Recommendation).
- In case of pulmonary edema or evidence of lung injury, the goal of therapy should include avoiding excessive fluid intake and judicious use of diuretics targeting euvolemia²¹ (Moderate Quality Evidence; Strong Recommendation).
- Standard management of heart failure is indicated with the exception that cerebral perfusion pres-

sure/mean arterial pressure (CPP/MAP) should be maintained as appropriate for the neurological condition²¹ (Moderate Quality Evidence; Strong Recommendation).

- Vigilant fluid balance management should be the foundation for monitoring intravascular volume status. While both noninvasive and invasive monitoring technologies are available, no specific modality can be recommended over clinical assessment^{21,23} (Moderate Quality Evidence; Weak Recommendation).
- Central venous lines should not be placed solely to obtain central venous pressure (CVP) measures and fluid management based solely on CVP measurements is not recommended²¹ (Moderate Quality Evidence; Strong Recommendation).
- Intravascular volume management should target euvolemia and avoid prophylactic hypervolemic therapy. In contrast, there is evidence for harm from aggressive administration of fluid aimed at achieving hypervolemia²¹ (High Quality Evidence; Strong Recommendation)²¹.
- Isotonic crystalloid is the preferred agent for volume replacement^{21,23} (Moderate Quality Evidence; Weak Recommendation).
- In patients with a persistent negative fluid balance, use of fludrocortisone or hydrocortisone may be considered²¹ (Moderate Quality Evidence; Weak Recommendation).

Hyponatremia

Hyponatremia following aSAH is the most common electrolyte imbalance and has prevalence rates of approximately 30%-55%¹⁷⁶⁻¹⁷⁸. Elevated levels of atrial natriuretic factor (ANF) and syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been implicated. Whether caused by SIADH or cerebral salt waste syndrome (CSW), hyponatremia in patients with aSAH has a clear association with increased morbidity, including cerebrovascular spasm^{176,179}. More recent work emphasizes that the diagnosis of CSW requires hypovolemia, whereas SIADH usually results in euvolemia or modest hypervolemia¹⁸⁰⁻¹⁸⁴. It appears that in aSAH, both entities may coexist in the same patient being manifested by excessive urine output with simultaneous

excessive free water retention^{180,181}. Generally the trigger used for treatment is a sodium concentration of <135 mEq/L or if neurological deterioration is attributed to falling sodium concentration²¹. According to recently published results of a retrospective, single-institution study, the etiology and treatment of hyponatremia vary in the presence of hypervolemia/euvolemia or hypovolemia. While treating these patients, differentiating between SIADH and CSW is essential¹⁸⁵. Controlled studies have been performed on the use of the corticosteroids fludrocortisone^{186,187} and hydrocortisone^{188,189} to prevent hyponatremia. Both corticosteroids were consistently effective in limiting excessive natriuresis and hyponatremia when started early after aSAH onset, but at the same time were associated with an increased incidence of treatable hyperglycemia and hypokalemia. Administration of isotonic fluid can prevent volume contraction but not hyponatremia. Use of slightly hypertonic sodium chloride (1.5% sodium chloride) at rates above maintenance requirements usually is efficacious for aSAH-induced hyponatremia. Data suggest that 3% saline may be safe but are too scant to assess its value in the management of hyponatremia¹⁹⁰.

Concerning the management of hyponatremia, it can be recommended according to current practice and general agreements that fluid restriction should not be used to treat hyponatremia; early treatment with hydrocortisone or fludrocortisone may be used to limit natriuresis and hyponatremia; mild hypertonic saline solutions can be used to correct hyponatremia; and free water intake *via* intravenous and enteral routes should be limited²¹. Furthermore, it should be emphasized that when hyponatremia in aSAH patients is treated promptly and appropriately, the patients' sodium levels return to normal without detrimental effects. Thus, it is strongly recommended to anticipate hyponatremia in patients with aSAH, timely detect and appropriately treat it to improve outcome¹⁹¹.

Recommendations for medical treatment of hyponatremia after aSAH

- Fluid restriction should not be used to treat hyponatremia²¹ (Weak Quality Evidence; Strong Recommendation).
- The use of fludrocortisone or hydrocortisone and hypertonic saline solution is reasonable for pre-

venting and correcting hyponatremia²² (Moderate Quality Evidence; Strong Recommendation). Early treatment with fludrocortisone or hydrocortisone may be used to limit natriuresis and hyponatremia²¹ (Moderate Quality Evidence; Weak Recommendation).

- Mild hypertonic saline solutions can be used to correct hyponatremia²¹ (Very Low Quality Evidence; Strong Recommendation).
- Extreme caution to avoid hypovolemia is needed if vasopressin-receptor antagonists are used for treatment of hyponatremia²¹ (Weak Quality Evidence; Strong Recommendation).
- Free water intake *via* intravenous and enteral routes should be limited²¹ (Very Low Quality Evidence; Strong Recommendation).

References

1. de ROOIJ NK, LINN FH, van der PLAS JA, ALGRA A, RINKEL GJ. Incidence of subarachnoid hemorrhage: a systematic review with emphasis on region, age, gender and time trends. *J Neurol Neurosurg Psychiatry* 2007;78:1365-72.
2. TRUELSSEN T, BONITA R, DUNCAN J, ANDERSON NE, MEE E. Changes in subarachnoid hemorrhage mortality, incidence and case fatality in New Zealand between 1981-1983 and 1991-1993. *Stroke* 1998;29:2298-303.
3. INGALL T, ASPLUND K, MAHONEN M, BONITA R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. *Stroke* 2000;31:1054-61.
4. JORDAN LC, JOHNSTON SC, WU YW, SIDNEY S, FULLERTON HJ. The importance of cerebral aneurysms in childhood hemorrhagic stroke: a population-based study. *Stroke* 2009;40:400-5.
5. SACCO S, TOTARO R, TONI D, MARINI C, CERONE D, CAROLEI A. Incidence, case-fatality and 10-year survival of subarachnoid hemorrhage in a population-based registry. *Eur Neurol* 2009;62:155-60.
6. LABOVITZ DL, HALIM AX, BRENT B, BODEN-ALBALA B, HAUSER WA, SACCO RL. Subarachnoid hemorrhage incidence among Whites, Blacks and Caribbean Hispanics: the Northern Manhattan Study. *Neuroepidemiology* 2006;26:147-50.
7. EDEN SV, MEURER WJ, SANCHEZ BN, LISABETH LD, SMITH MA, BROWN DL, MORGENSTERN LB. Gender and ethnic differences in subarachnoid hemorrhage. *Neurology* 2008;71:731-5.
8. PAKARINEN S. Incidence, etiology and prognosis of primary subarachnoid hemorrhage. A study based on 589 cases

- diagnosed in a defined urban population during a defined period. *Acta Neurol Scand* 1967;43(29):1-128.
9. HUANG J, van GELDER JM. The probability of sudden death from rupture of intracranial aneurysms: a meta-analysis. *Neurosurgery* 2002;51:1101-5.
 10. PHILLIPS LH 2nd, WHISNANT JP, O'FALLON WM, SUNDT TM Jr. The unchanging pattern of subarachnoid hemorrhage in a community. *Neurology* 1980;30:1034-40.
 11. JANE JA, KASSELL NF, TORNER JC, WINN HR. The natural history of aneurysms and arteriovenous malformations. *J Neurosurg* 1985;62:321-3.
 12. WINN HR, RICHARDSON AE, O'BRIEN W, JANE JA. The long-term prognosis in untreated cerebral aneurysms. II Late morbidity and mortality. *Ann Neurol* 1978;4:418-26.
 13. NISHIOKA H, TORNER JC, GRAF JC, KASSELL NF, SAHS AL, GOETTLER LC. Cooperative study of intracranial aneurysms and subarachnoid hemorrhage: a long-term prognostic study. II Ruptured intracranial aneurysms managed conservatively. *Arch Neurol* 1984;41:1142-6.
 14. HOP JW, RINKEL GJ, ALGRA A, van GIJN J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. *Stroke* 1997;28:660-4.
 15. INAGAWA T. Trends in incidence and case fatality rates of aneurysmal subarachnoid hemorrhage in Izumo City, Japan, between 1980-1989 and 1990-1998. *Stroke* 2001;32:1499-507.
 16. NIEUWKAMP DJ, SETZ LE, ALGRA A, LINN FH, de ROOIJ NK, RINKEL GJ. Changes in case fatality of aneurysmal subarachnoid hemorrhage over time, according to age, sex and region: a meta-analysis. *Lancet Neurol* 2009;8:635-42.
 17. JUVELA S. Prehemorrhage risk factors for fatal intracranial aneurysm rupture. *Stroke* 2003;34:1852-7.
 18. KASSELL NF, TORNER JC, HALEY EC, JANE JA, ADAMS HP, KONGALE GL. The International Cooperative Study on the timing of aneurysm surgery. Part 1. Overall management results. *J Neurosurg* 1990;73:18-36.
 19. JUVELA S. Alcohol consumption as a risk factor for poor outcome after aneurysmal subarachnoid hemorrhage. *BMJ* 1992;304:1663-7.
 20. WEIRBK, KONGABLE GL, KASSELL NF, SCHULTZ JR, TRUSKOWSKI LL, SIGREST A. Cigarette smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: a report of the Cooperative Aneurysm Study. *J Neurosurg* 1998;89:405-11.
 21. DIRINGER MN, BLECK TP, HEMPHILL JC III, MENON D, SHUTTER L, VESPA P, *et al.* Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. *Neurocrit Care* 2011;15:211-40.
 22. CONOLLY ES Jr, RABINSTEIN AA, CARHUAPOMA JR, DERDEYN CP, DION J, HIGASHIDA RT, *et al.*, on behalf of the American Heart Association Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Council on Cardiovascular Surgery and Anesthesia and Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2012;43(6):1711-37.
 23. STEINER T, JUVELA S, UNTERBERG A, JUNG C, FORSTING M, RINKEL G. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid hemorrhage. *Cerebrovasc Dis* 2013;35:93-112.
 24. POLJAKOVIĆ Z, ŠUPE S, MATIJEVIĆ V, RADOŠ M, PALADINO J, ALVIR D, *et al.* Basic algorithm for management of patients with aneurysmal subarachnoid hemorrhage. *Neurol Croat* 2012;61(3-4):43-52.
 25. ATKINS D, BEST D, BRISS PA, ECCLES M, FALCK-YTER Y, FLOTTORP S, *et al.* Grading quality of evidence and strength of recommendations. *BMJ* 2004;328(7454):1490.
 26. DUPONT S, RABINSTEIN AA. CT evaluation of lateral ventricular dilatation after subarachnoid hemorrhage: baseline bicaudate index values. *Neurol Res* 2013;35(2):103-6.
 27. WOERNLE CM, WINKLER KM, BURKHARDT JK, HAILE SR, BELLUT D, NEIDERT MC, *et al.* Hydrocephalus in 389 patients with aneurysm-associated subarachnoid hemorrhage. *J Clin Neurosci* 2013;20(6):824-6.
 28. STEIN M, LUECKE M, PREUSS M, BOEKER DK, JOEDICKE A, OERTEL MF. Spontaneous intracerebral hemorrhage with ventricular extension and the grading of obstructive hydrocephalus: the prediction of outcome of a special life-threatening entity. *Neurosurgery* 2010;67(5):1243-51.
 29. RINCON F, GORDON E, STARKE RM, BUITRAGO MM, FERNANDEZ A, SCHMIDT JM, *et al.* Predictors of long-term shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: clinical article. *J Neurosurg* 2010;113:774-80.
 30. O'KELLY CJ, KULKARNI AV, AUSTIN PC, URBACH D, WALLACE MC. Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: incidence, predictors and revision rates: clinical article. *J Neurosurg* 2009;111:1029-35.
 31. JARTTI P, KARTTUNEN A, ISOKANGAS JM, JARTTI A, KOSKELAINEN T, TERVONEN O. Chronic hydrocephalus after neurosurgical and endovascular treatment of ruptured intracranial aneurysms. *Acta Radiol* 2008;49:680-6.
 32. HASAN D, TANGHE HL. Distribution of cisternal blood in patients with acute hydrocephalus after subarachnoid hemorrhage. *Ann Neurol* 1992;31:374-8.
 33. SHAH AH, KOMOTAR RJ. Pathophysiology of acute hydrocephalus after subarachnoid hemorrhage. *World Neurosurg*. 2013 Feb 1. doi:pii: S1878-8750(13)00209-X.

34. RANSOM ER, MOCCO J, KOMOTAR RJ, SAHNI D, CHANG J, HAHN DK, *et al.* External ventricular drainage response in poor grade aneurysmal subarachnoid hemorrhage: effect on preoperative grading and prognosis. *Neurocrit Care* 2007;6:174-80.
35. HEROS RC. Acute hydrocephalus after subarachnoid hemorrhage. *Stroke* 1989;20:715-7.
36. AUER LM, MOKRY M. Disturbed cerebrospinal fluid circulation after subarachnoid hemorrhage and acute aneurysm surgery. *Neurosurgery* 1990;26:804-8.
37. PARE L, DELFINO R, LEBLANC R. The relationship of ventricular drainage to aneurysmal rebleeding. *J Neurosurg* 1992;76:422-7.
38. HELLINGMAN CA, van der BERGH WM, BEIJER IS, van DIJK GW, ALGRA A, van GIJN J, *et al.* Risk of rebleeding after treatment of acute hydrocephalus in patients with aneurysmal subarachnoid hemorrhage. *Stroke* 2007;38:96-9.
39. McIVERJI, FRIEDMANJA, WIJDIKES EF, PIEPGRAS DG, PICHELMANN MA, TOUSSAINT LG 3rd, *et al.* Preoperative ventriculostomy and rebleeding after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2002;97:1042-4.
40. BOTA DP, LEFRANC F, VILALLOBOS HR, BRIMIOULLE S, VINCENT JL. Ventriculostomy-related infections in critically ill patients: a 6 year experience. *J Neurosurg* 2005;103:468-72.
41. BAILES JE, SPETZLER RF, HADLEY MN, BALDWIN HZ. Management, morbidity and mortality of poor-grade aneurysm patients. *J Neurosurg* 1990;73:559-66.
42. HUTTNER HB, SCHWAB S, BARDUTZKY J. Lumbar drainage for communicating hydrocephalus after ICH with ventricular hemorrhage. *Neurocrit Care* 2006;5:193-6.
43. HUTTNER HB, NAGEL S, TOGNONI E, KOHRMANN M, JUTTLER E, ORAKCIOGLU B, *et al.* Intracerebral hemorrhage with severe ventricular involvement: lumbar drainage for communicating hydrocephalus. *Stroke* 2007;38:183-7.
44. KLIMO P Jr, KESTLE JR, MacDONALD JD, SCHMIDT RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. *J Neurosurg* 2004;100:215-24.
45. KWON OY, KIM YJ, CHO CS, LEE SK, CHO MK. The utility and benefits of external lumbar CSF drainage after endovascular coiling on aneurysmal subarachnoid hemorrhage. *J Korean Neurosurg Soc* 2008;43:281-7.
46. HASAN D, LINDSAY KW, VERMEULEN M. Treatment of acute hydrocephalus after subarachnoid hemorrhage with serial lumbar puncture. *Stroke* 1991;22:190-4.
47. LITTLE AS, ZABRAMSKI JM, PETERSON M, GOSLAR PW, WAIT SD, ALBUQUERQUE FC, *et al.* Ventriculoperitoneal shunting after aneurysmal subarachnoid hemorrhage: analysis of the indications, complications and outcome with a focus on patients with borderline ventriculomegaly. *Neurosurgery* 2008;62:618-27.
48. de OLIVEIRA JG, BECK J, SETZER M, GERLACH R, VATTER H, SEIFERT V, *et al.* Risk of shunt-dependent hydrocephalus after occlusion of ruptured intracranial aneurysm by surgical clipping or endovascular coiling: a single-institution series and meta-analysis. *Neurosurgery* 2007;61:924-33.
49. DORAI Z, HYNAN LS, KOPITNIK TA, SAMSON D. Factors related to hydrocephalus after aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2003;52:763-9.
50. MURAJ, ROJAS-ZALAZAR D, RUIZ A, VINTIMILLA LC, MARENGO JJ. Improve outcome in high-grade aneurysmal subarachnoid hemorrhage by enhancement of endogenous clearance of cisternal blood clots: a prospective study that demonstrates the role of lamina terminalis fenestration combined with modern microsurgical cisternal blood evacuation. *Minim Invasive Neurosurg* 2007;50:355-62.
51. SETHI H, MOORE A, DERVIN J, CLIFTON A, MacSWEENEY JE. Hydrocephalus: comparison of clipping and embolization in aneurysm treatment. *J Neurosurg* 2000;92:991-4.
52. KOMOTAR RJ, HAHN DK, KIM GH, STARKE RM, GARRETT MC, MERKOW MB, *et al.* Efficacy of lamina terminalis fenestration in reducing shunt-dependent hydrocephalus following aneurysmal subarachnoid hemorrhage: a systemic review: clinical article. *J Neurosurg* 2009;111:147-54.
53. TANNO Y, HOMMA M, OINUMA M, KODAMA N, YMAMOTO T. Rebleeding from ruptured intracranial aneurysms in North Eastern Province of Japan: a cooperative study. *J Neurol Sci* 2007;258:11-6.
54. OHKUMA H, TSURUTANI H, SUZUKI S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. *Stroke* 2001;32:1176-80.
55. NAIDECH AM, JANJUA N, KREITER KT, OSTAPKOVICH ND, FITZSIMMONS BF, PARRA A, *et al.* Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. *Arch Neurol* 2005;62:410-6.
56. FUJII Y, TAKEUCHI S, SASAKI O, MINAKAWA T, KOIKE T, TANAKA R. Ultra-early rebleeding in spontaneous subarachnoid hemorrhage. *J Neurosurg* 1996;84:35-42.
57. CHA KC, KIM JH, KANG HI, MOON BG, LEE SJ, KIM JS. Aneurysmal rebleeding: factors associated with clinical outcome in the rebleeding patients. *J Korean Neurosurg Soc* 2010;47:119-23.
58. HIJDR A, VERMEULEN M, van GIJN J, van CREVEL R. Rupture of intracranial aneurysms: a clinicoanatomic study. *J Neurosurg* 1987;67:29-31.
59. GUO LM, ZHOU HY, XU JW, WANG Y, QIU YM, JIANG JY. Risk factors related to aneurysmal rebleeding. *World Neurosurg* 2011;76(3-4):292-8.
60. STARKE RM, CONNOLLY ES Jr; participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Rebleeding after aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2011;15(2):241-6.

61. WU TC, TSUI YK, CHEN TY, LIN CJ, WU TC, TZ-ENG WS. Rebleeding of aneurysmal subarachnoid hemorrhage in computed tomography angiography: risk factor, rebleeding pattern, and outcome analysis. *J Comput Assist Tomogr* 2012;36(1):103-8.
62. RUIGROM YM, SLOOTER AJ, RINKEL GJ, WIJMEGA C, ROSENDAAL FR. Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage and subsequent complication of secondary cerebral ischemia and rebleeding. *Acta Neurochir (Wien)* 2010;152:257-62.
63. TONG Y, GU J, FAN WJ, YU JB, PAN JW, WAN S, *et al.* Patients with supratentorial aneurysmal subarachnoid hemorrhage during the intermediate period: waiting or actively treating. *Int J Neurosci* 2009;119:1494-506.
64. WIJDICKS EF, VERMEULEN M, MURRAY GD, HIJDRA A, van GIJN J. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. *Clin Neurol Neurosurg* 1990;92:111-7.
65. LIU-DERYKE X, JANISSE J, COPLIN WM, PARKER DJ, NORRIS G, RHONEY DH. A comparison of nicardipine and labetalol for acute hypertension management following stroke. *Neurocrit Care* 2008;9:167-76.
66. RITERBERG BZ, HARDMAN J, URBANIAK K, MERCHANT A, MANGUBAT EZ, ALARAJ A, *et al.* Prospective randomized comparison of safety and efficacy of nicardipine and nitroprusside drip for control of hypertension in the neurosurgical intensive care unit. *Neurosurgery* 2008;63:115-21.
67. NAROTAM PK, PURI V, ROBERTS JM, TAYLOR C, VORA Y, NATHOO N. Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. *J Neurosurg* 2008;109:1065-74.
68. SIIRONEN J, JUVELA S, VARIS J, PORRAS M, POUSSA K, ILVESKERO S, *et al.* No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized double-blind, placebo-controlled clinical trial. *J Neurosurg* 2003;99:953-9.
69. JUVELA S, SIIRONEN J, VARIS J, POUSSA K, PORRAS M. Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2005;102:194-201.
70. ROOS YB, RINKEL GJ, VERMEULEN M, ALGRA A, van GIJN J. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage. *Cochrane Database Syst Rev* 2003;CD001245.
71. STARKE RM, KIM GH, FERNANDEZ A, KOMOTAR RJ, HICKMAN ZL, OTTEN ML, *et al.* Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. *Stroke* 2008;29:2617-21.
72. HILLMAN J, FRIDRIKSSON S, NILSSON O, YU Z, SAVELAND H, JAKOBSSON KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. *J Neurosurg* 2002;97:771-8.
73. RINKEL GJ, KLIJN CJ. Prevention and treatment of medical and neurological complications in patients with aneurysmal subarachnoid hemorrhage. *Pract Neurol* 2009;9:195-209.
74. KUSUMI M, YAMADA M, KITAHARA T, *et al.* Rerupture of cerebral aneurysms during angiography – a retrospective study of 13 patients with subarachnoidal hemorrhage. *Acta Neurochir (Wien)* 2005;147:831-7.
75. SAITOH H, HAYAKAWA K, NISHIMURA K, *et al.* Rerupture of cerebral aneurysms during angiography. *AJNR Am J Neuroradiol* 1995;16:539-42.
76. INAGAWA T. Ultra-early rebleeding within six hours after aneurysmal rupture. *Surg Neurol* 1994;42(2):130-4.
77. KOMIYAMA M, TAMURA K, NAGATA Y, FU Y, YAGURA H, YASUI T. Aneurysmal rupture during angiography. *Neurosurgery* 1993;33:798-803.
78. JAEGER M, SOEHLE M, SCHUMANN MU, MEIXENSBERGER J. Clinical significance of impaired cerebrovascular autoregulation after severe aneurysmal subarachnoid hemorrhage. *Stroke* 2012;43(8):2097-101.
79. VERGOUWEN MD, VERMEULEN M, van GIJN J, *et al.* Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies. Proposal of a Multidisciplinary Research Group. *Stroke* 2010;41:2391-5.
80. SIMARD JM, SCHREIBMAN D, ALDRICH EF, STALLMEYER B, LE B, JAMES RF, BEATY N. Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage. *Neurocrit Care* 2010;13(3):439-49.
81. SACCO RL, KASNER SE, BRODERICK JP, CAPLAN LR, CONNORS JJ, CULEBRAS A, *et al.* An updated definition of the stroke for the 21st century: a statement for the healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2013;44(7):2064-89.
82. BROWN RJ, KUMAR A, DHAR R, SAMPSON TR, DIRINGER MN. The relationship between delayed infarcts and angiographic vasospasm after aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 2013;72(5):702-8.
83. MILLS JN, MEHTA V, RUSSIN J, AMAR A, RAJAMOHAN A, MACK WJ. Advanced imaging modalities in the detection of cerebral vasospasm. *Neurol Res Int* 2013;2013:415960, doi: 10.1155/2013/415960.
84. FRONTERA JA, FERNANDEZ A, SCHMIDT JM, *et al.* Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? *Stroke* 2009;40:1963-8.
85. KREITER KT, MAYER SA, HOWARD G, *et al.* Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. *Stroke* 2009;40:2362-7.

86. VERGOUWEN MD, ETMINAN N, ILODIGWE D, MacDONALD RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. *J Cereb Blood Flow Metab* 2011;31:1545-53.
87. RABINSTEIN AA, WEIGAND S, ATKINSON JL, WILDICKS EF. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. *Stroke* 2005;36:992-7.
88. SCHMIDT JM, WARTENBERG KE, FERNANDEZ A, *et al.* Frequency and clinical impact of asymptomatic cerebral infarction due to vasospasm after subarachnoid hemorrhage. *J Neurosurg* 2008;109:1052-9.
89. SHIMODA M, TAKEUCHI M, TOMINAGA J, ODA S, KUMASAKA A, TSUGANE R. Asymptomatic *versus* symptomatic infarcts from vasospasm in patients with subarachnoid hemorrhage: serial magnetic resonance imaging. *Neurosurgery* 2001;49:1341-8.
90. CHAUDHARY SR, KO N, DILLON WP, *et al.* Prospective evaluation of multidetector-row CT angiography for the diagnosis of vasospasm following subarachnoid hemorrhage: a comparison with digital subtraction angiography. *Cerebrovasc Dis* 2008;25:144-50.
91. YOON DY, CHOI CS, KIM KH, CHO BM. Multidetector-row CT angiography of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: comparison of volume-rendered images and digital subtraction angiography. *AJNR Am J Neuroradiol* 2006;27:370-7.
92. WINTERMARK M, KO NU, SMITH WS, LIU S, HIGASHIDA RT, DILLON WP. Vasospasm after subarachnoid hemorrhage: utility of perfusion CT and CT angiography on diagnosis and management. *AJNR Am J Neuroradiol* 2006;27:26-34.
93. WINTERMARK M, DILLON WP, SMITH WS, *et al.* Visual grading system for vasospasm based on perfusion CT imaging: comparisons with conventional angiography and quantitative perfusion CT. *Cerebrovasc Dis* 2008;26:163-70.
94. CARRERA E, SCHMIDT JM, ODDO M, *et al.* Transcranial doppler for predicting delayed cerebral ischemia after subarachnoid hemorrhage. *Neurosurgery* 2009;65:316-23.
95. LYSAKOWSKI C, WALDER B, COSTANZA MC, TRAMER MR. Transcranial Doppler *versus* angiography in patients with vasospasm due to a ruptured cerebral aneurysm: a systematic review. *Stroke* 2001;32:2292-8.
96. LINDEGAARD KF, NORNES H, BAKKE SJ, SORTEBERG W, NAKSTAD P. Cerebral vasospasm diagnosis by means of angiography and blood velocity measurements. *Acta Neurochir* 1989;100(1-2):12-24.
97. SVIRI GE, GHODKE B, BRITZ GW, *et al.* Transcranial Doppler grading criteria for basilar artery vasospasm. *Neurosurgery* 2006;59(2):360-5.
98. RORDORF G, KOROSHETZ WJ, COPEN WA, *et al.* Diffusion- and perfusion-weighted imaging in vasospasm after subarachnoid hemorrhage. *Stroke* 1999;30(3):599-605.
99. SLOAN MA, ALEXANDROV AV, TEGELER CH, *et al.* Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2004;62:1468-81.
100. LAM JMK, SMIELEWSKI P, CZOSNYKA M, PICKARD JD, KIRKPATRICK PJ. Predicting delayed ischemic deficits after aneurysmal subarachnoid hemorrhage using a transient hyperemic response test of cerebral autoregulation. *Neurosurgery* 2000;47(4):819-25.
101. EDMONDS HL Jr, ISLEY MR, SLOAN TB, ALEXANDROV AV, RAZUMOWSKY AY. American Society of Neurophysiologic Monitoring and American Society of Neuroimaging joint guidelines for transcranial doppler ultrasonic monitoring. *J Neuroimaging* 2011;21(2):177-83.
102. ROJE-BEDEKOVIĆ M, LOVRENČIĆ-HUZJAN A, BOSNAR-PURETIĆ M, DEMARIN V. Prolonged mean reaction time in posterior cerebral artery during visual stimulation in patients with severe carotid disease. *Clin Physiol Funct Imaging* 2011;31(3):169-74.
103. MEIXENSBERGER J, VATH A, JAEGER M, KUNZE E, DINGS J, ROOSEN K. Monitoring of brain tissue oxygenation following severe subarachnoid hemorrhage. *Neurol Res* 2003;25:445-50.
104. SARRAFZADEH A, HAUX D, PLOTKIN M, LUDEMANN L, AMTHAUER H, UNTERBERG A. Bedside microdialysis reflects dysfunction of cerebral energy metabolism in patients with aneurysmal subarachnoid hemorrhage as confirmed by 15 O-H₂ O-PET and 18 F-FDG-PET. *J Neuroradiol* 2005;32:638-43.
105. STUART RM, WAZIRI A, WEINTRAUB D, *et al.* Intracortical EEG for the detection of vasospasm in patients with poor-grade subarachnoid hemorrhage. *Neurocrit Care* 2010;13:355-8.
106. BREITENFELD T, VARGEK SOLTER V, SUPANČ V, ROJE-BEDEKOVIĆ M, DEMARIN V. Stroke unit – where all stroke patients should be treated. *Acta Clin Croat* 2009;48(3):341-4.
107. YUNDT KD, GRUBB RL, DIRINGER MN, POWERS WJ. Autoregulatory vasodilatation of parenchymal vessels is impaired during cerebral vasospasm. *J Cereb Blood Flow Metab* 1998;18:419-24.
108. TAKEUCHI H, HANDA Y, KOBAYASHI H, KAWANO H, HAYASHI M. Impairment of cerebral autoregulation during the development of chronic cerebral vasospasm after subarachnoid hemorrhage in primates. *Neurosurgery* 1991;28:41-8.
109. ADAMCZYK P, HE S, AMAR AP, MACK WJ. Medical management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a review of current and emerging therapeutic interventions. *Neurol Res Int* 2013;2013:462491.
110. DORHOUT MEES SM, RINKEL GJ, FEIGIN VL, ALGRA A, van der BERGH WM, VERMEULEN M, *et*

- al.* Calcium antagonists for aneurysmal subarachnoid hemorrhage. *Cochrane Database Syst Rev* 2007;38:183-7.
111. SIASIOS I, KAPSALAKI EZ, FOUNTA KN. Cerebral vasospasm pharmacological treatment: an update. *Neurol Res Int* 2013;2013:571328.
 112. BEDERSON JB, CONNOLLY ES Jr, BATJER HH, *et al.* Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 2009;40(3):994-1025.
 113. PICKARD JD, MURRAY GD, ILLINGWORTH R, SHAW MD, TEASDALE GM, FOY PM, *et al.* Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British Aneurysm Nimodipine Trial. *BMJ* 1989;298:636-42.
 114. RAY WZ, MORAN CJ, DERDEYN CP, DIRINGER MN, DACEYRG Jr, ZIPFEL GJ. Near-complete resolution of angiographic vasospasm after extreme elevation of mean arterial pressure: case report. *Surg Neurol* 2009;72:347-53.
 115. CONNOLLY ES Jr, RABINSTEIN AA, CARHUAPOMA JR, *et al.* Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2012;43(6):1711-37.
 116. MacDONALD RL, KASSELL NF, MAYER S, *et al.* Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. *Stroke* 2008;39(11):3015-21.
 117. DANKBAAR JW, SLOOTER AJ, RINKEL GJ, SCHAAF IC. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid hemorrhage: a systematic review. *Crit Care* 2010;14:R23.
 118. LENNIHAN L, MAYER SA, FINK ME, BECKFORD A, PAIK MC, ZHANG H, *et al.* Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized control trial. *Stroke* 2000;31:383-91.
 119. ZWIENENBERG-LEE M, HARTMAN J, RUDISILL N, MADDEN LK, SMITH K, ESKRIDGE J, *et al.* Balloon Prophylaxis for Aneurysmal Vasospasm (BPAV) Study Group. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. *Stroke* 2008;39:1759-65.
 120. DORHOUT MEES SM, van der BERGH WM, ALGRA A, RINKEL GJ. Antiplatelet therapy for aneurysmal subarachnoid hemorrhage. *Cochrane Database Syst Rev* 2007;4:CD006184.
 121. KLIMO P Jr, KESTLE JR, MacDONALD JD, SCHMIDT RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. *J Neurosurg* 2004;100(2):215-24.
 122. KRAMER AH, FLETCHER JJ. Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *Neurocrit Care* 2011;14(3):489-99.
 123. STAYKOV D, SCHWAB S. Clearing bloody cerebrospinal fluid: clot lysis, neuroendoscopy and lumbar drainage. *Curr Opin Crit Care* 2013;19(2):92-100.
 124. MacDONALD RL, HIGASHIDA RT, KELLER E, MAYER SA, MOLYNEUX A, RAABE A, *et al.* Clazosentan, an endothelial receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping: a randomized, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). *Lancet Neurol* 2001;10:618-25.
 125. DORHOUT MEES SM, van der BERGH WM, ALGRA A, RINKEL GJ. Achieved serum magnesium concentrations and occurrence of delayed cerebral ischemia and poor outcome in aneurysmal subarachnoid hemorrhage. *J Neurol Neurosurg Psychiatry* 2007;78:729-31.
 126. MEES SM, ALGRA A, VANDERTOP WP, van KOOTEN F, KUIJSTEN HA, BOITEN J, *et al.* Magnesium for aneurysmal subarachnoid hemorrhage (MASH-2): a randomized placebo-controlled trial. *Lancet* 2012;380:44-9.
 127. WONG GK, POON WS, CHAN MT, BOET R, GIN T, NG SC, *et al.*; IMASH Investigators. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. *Stroke* 2010;41:921-6.
 128. AMIN-HANJANI S, STAGLIANO NE, YAMADA M, HUANG PL, LIAO JK, MOSKOWITZ MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. *Stroke* 2001;32(4):980-5.
 129. LAUFS U, La FATA V, LIAO JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. *J Biol Chem* 1997;272(50):31725-9.
 130. YAMADA M, HUANG Z, DALKARA T, *et al.* Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. *J Cereb Blood Flow Metab* 2000;20(4):709-17.
 131. TSENG MY, CZOSNYKA M, RICHARDS H, PICKARD JD, KIRKPATRICK PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. *Stroke* 2005;36(8):1627-32.
 132. LYNCH JR, WANG H, McGIRT MJ, *et al.* Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. *Stroke* 2005;36(9):2024-6.
 133. SATOH S-I, KOBAYASHI T, HITOMI A, *et al.* Inhibition of neutrophil migration by a protein kinase inhibitor for

- the treatment of ischemic brain infarction. *Jpn J Pharmacol* 1999;80(1):41-8.
134. SOBEY CG. Cerebrovascular dysfunction after subarachnoid haemorrhage: novel mechanisms and directions or therapy. *Clin Exp Pharmacol Physiol* 2001;28(11):926-9.
 135. MacDONALD RL, PLUTA RM, ZHANG JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. *Nat Clin Pract Neurol* 2007;3(5):256-63.
 136. WOITZIK J, DREIER JP, HECHT N, *et al.* Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. *J Cereb Blood Flow Metab* 2012;32(2):203-12.
 137. UKKOLA V, HEIKKINEN ER. Epilepsy after operative treatment of ruptured cerebral aneurysm. *Acta Neurochir (Wien)* 1990;106:115-8.
 138. CHOI KS, CHUN HJ, YI HJ, KO Y, KIM YS, KIM JM. Seizures and epilepsy following aneurysmal subarachnoid hemorrhage: incidence and risk factors. *J Korean Neurosurg Soc* 2009;46:93-8.
 139. CABRAL NL, GONCALVES AR, LONGO AL, MORO CH, COSTA G, AMARAL CH, *et al.* Incidence of stroke subtypes, prognosis and prevalence of risk factors in Joinville, Brasil: a 2 year community based study. *J Neurol Neurosurg Psychiatry* 2009;80:755-61.
 140. KHAM DA, LOFTUS CM, COPELAND B, QUEST DO. Seizures during the immediate postoperative period. *Neurosurgery* 1983;12:14-7.
 141. MATTHEW E, SHERWIN AL, WELNER SA, ODU-SOTE K, STRATFORD JG. Seizures following intracranial surgery: incidence in the first postoperative week. *Can J Neurol Sci* 1980;7:285-90.
 142. KOTILA M, WALTIMO O. Epilepsy after stroke. *Epilepsia* 1992;33:495-8.
 143. OHMAN J. Hypertension as a risk factor for epilepsy after aneurysmal subarachnoid hemorrhage and surgery. *Neurosurgery* 1990;27:578-81.
 144. RHONEY DH, TIPPS LB, MURRY KR, BASHAM MC, MICHAEL DB, COPLIN WM. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. *Neurology* 2000;55:258-65.
 145. MOLYNEUX AJ, KERR RS, YU LM, *et al.* International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping *versus* coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups and aneurysm occlusion. *Lancet* 2005;366:809-17.
 146. CLAASSEN J, PEERY S, KREITER KT, *et al.* Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. *Neurology* 2003;60:208-14.
 147. BYRNE JV, BOARDMAN P, IOANNIDIS I, ADCOCK J, TRAILL Z. Seizures after aneurysmal subarachnoid hemorrhage treated with coil embolization. *Neurosurgery* 2003;52:545-52.
 148. NAIDECH AM, KREITER KT, JANJUA N, *et al.* Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. *Stroke* 2005;36:583-7.
 149. ROSENGART AJ, HUO JD, TOLENTINO J, *et al.* Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. *J Neurosurg* 2007;107:253-60.
 150. CHUMNANVEJ S, DUNN IF, KIM DH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. *Neurosurgery* 2007;60:99-102.
 151. HART RG, BYER JA, SLAUGHTER JR, HEWETT JE, EASTON JD. Occurrence and implications of seizures in subarachnoid hemorrhage due to ruptured intracranial aneurysms. *Neurosurgery* 1981;8:417-21.
 152. O'LAOIRE SA. Epilepsy following neurosurgical intervention. *Acta Neurochir Suppl (Wien)* 1990;50:52-4.
 153. MIŠKOV S, BOŠNJAK J, ROJE BEDEKOVIĆ M, MIKULA I, DEŽMALJ GRBELJA L, KOPAČEVIĆ L, DEMARIN V, BAŠIĆ KES V. Stroke – the most important cause of the newly diagnosed epilepsy in the elderly. *Period Biol* 2012;114(3):429-33.
 154. BUTZKUEVEN H, EVANS AH, PITMAN A, LEOPOLD C, JOLLEY DJ, KAYE AH, *et al.* Onset seizures independently predict poor outcome after subarachnoid hemorrhage. *Neurology* 2000;55:1315-20.
 155. DENNIS LJ, CLAASSEN J, HIRCH LJ, EMERSON RG, CONNOLLY ES, MAYER SA. Nonconvulsive status epilepticus after subarachnoid hemorrhage. *Neurosurgery* 2002;51:1136-43.
 156. LITTLE AS, KERRIGAN JF, McDOUGALL CG, ZABRAMSKI JM, ALBUQUERQUE FC, NAKAJI P, *et al.* Nonconvulsive status epilepticus in patients suffering spontaneous subarachnoid hemorrhage. *J Neurosurg* 2007;106:805-11.
 157. LEE VH, OH JK, MULVAGH SL, WIJDICKS EF. Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 2006;5(3):243-9.
 158. ZAROFF JG, RORDORF GA, NEWELL JB, OGILVY CS, LEVINSON JR. Cardiac outcome in patients with subarachnoid hemorrhage and electrocardiographic abnormalities. *Neurosurgery* 1999;44:34-9.
 159. FRONTERA JA, PARRA A, SHIMBO D, FERNANDEZ A, SCHMIDT JM, PETER P, *et al.* Cardiac arrhythmias after subarachnoid hemorrhage: risk factors and impact on outcome. *Cerebrovasc Dis* 2008;26(1):71-8.
 160. JEONG YS, KIM HD. Clinically significant cardiac arrhythmia in patients with aneurysmal subarachnoid hemorrhage. *J Cerebrovasc Endovasc Neurosurg* 2012;14(2):90-4.
 161. SOMMARGREN CE, ZAROFF JG, BANKI N, DREW BJ. Electrocardiographic repolarization abnormalities in subarachnoid hemorrhage. *J Electrocardiol* 2002;5:257-62.

162. BROUWERS PJAM, WIJDICKS EFM, HASAN D, VERMEULEN M, WEVER EFD, FRERICKS H, *et al.* Serial electrocardiographic recording in aneurysmal subarachnoid hemorrhage. *Stroke* 1989; 20:1162-7.
163. TUNG P, KOPELNIK A, BANKI N, ONG K, KO N, LAWTON MT, *et al.* Predictors of neurocardiogenic injury after subarachnoid hemorrhage. *Stroke* 2004;35:548-53.
164. HOROWITZ MB, WILLET D, KEFFER J. The use of cardiac troponin-I (cTnI) to determine the incidence of myocardial ischemia and injury in patients with aneurysmal and presumed aneurysmal subarachnoid hemorrhage. *Acta Neurochir (Wien)* 1998;140:87-93.
165. PAREKH N, VENKATESH B, CROSS D, LEDITSCHKE A, ATHERTON J, MILES W, *et al.* Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. *J Am Coll Cardiol* 2000;36:1328-35.
166. ELRIFAI AM, BAILES JE, SHIH SR, DIANZUMBA S, BRILLMAN J. Characterization of the cardiac effects of acute subarachnoid hemorrhage in dogs. *Stroke* 1996;27:737-41.
167. OTOMO S, TASHIMO M, SHIMODA O. Two cases of transient left ventricular apical ballooning syndrome associated with subarachnoid hemorrhage. *Anesth Analg* 2006;103:58358-66.
168. LEE VH, CONOLLY HM, FULGHAM JR, MANNO EM, BROWN RD Jr, WIJDICKS EF. Tako-tsubo cardiomyopathy in aneurysmal subarachnoid hemorrhage: an underappreciated ventricular dysfunction. *J Neurosurg* 2006;105:264-70.
169. KURISU S, SATO H, KAWAGOE T, ISHIHARA M, SHIMATANI Y, NISHIOKA K, *et al.* Tako-tsubo-like left ventricular dysfunction with ST segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. *Am Heart J* 2002;143:448-55.
170. WITTSTEIN IS, THIEMANN DR, LIMA JAC, BAUGHMAN KL, SCHULMAN SP, GERSTENBLITH G, *et al.* Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med* 2005;352:539-48.
171. FRIEDMAN JA, PICHELMANN MA, PIEOGRAS DG, *et al.* Pulmonary complications of aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2003;52:1025-31.
172. SOLENSKI NJ, HALEY EC Jr, KASSELL NF, *et al.* Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. *Crit Care Med* 1995;23:1007-17.
173. ŠERIĆ V, ROJE BEDEKOVIĆ M, DEMARIN V. Neurogenic pulmonary edema. *Acta Clin Croat* 2004;43:389-95.
174. INAMASU J, SUGIMOTO K, YAMADA Y, GANAHA T, ITO K, WATABE T, *et al.* The role of catecholamines in the pathogenesis of neurogenic pulmonary edema associated with subarachnoid hemorrhage. *Acta Neurochir (Wien)* 2012;154(12):2179-84.
175. FRIEDMAN JA, PICHELMANN MA, PIEOGRAS DG, *et al.* Pulmonary complications of aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2003;52:1025-31.
176. COGHLAN LA, HINDMAN BJ, BAYMAN EO, *et al.* Independent associations between electrocardiographic abnormalities and outcomes in patients with aneurysmal subarachnoid hemorrhage: findings from the Intraoperative Hypothermia Aneurysm Surgery Trial. *Stroke* 2009;40:412-8.
177. SHERLOCK M, O'SULLIVAN E, AGHA A, BEHAN LA, RAWLUK D, BRENNAN P, *et al.* The incidence and pathophysiology of hyponatremia after subarachnoid hemorrhage. *Clin Endocrinol* 2006;64:250-4.
178. CHANDY D, SY R, ARONOW WS, LEE WN, MAGUIRE G, MURALI R. Hyponatremia and cerebrovascular spasm in aneurysmal subarachnoid hemorrhage. *Neurol India* 2006;54:273-5.
179. QURESHI AI, SURI MF, SUNG GY, *et al.* Prognostic significance of hypernatremia or hyponatremia among patients with aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2002;50:749-55.
180. RAHMAN M, FRIEDMAN WA. Hyponatremia in neurosurgical patients: clinical guidelines development. *Neurosurgery* 2009;65:925-35.
181. DIRINGER MN, WU KC, VERBALIS JG, HANLEY DF. Hypervolemic therapy prevents volume contraction but not hyponatremia following subarachnoid hemorrhage. *Ann Neurol* 1992;31:543-50.
182. AUDIBERT G, STEINMANN G, de TALANCE N, *et al.* Endocrine response after severe subarachnoid hemorrhage related to sodium and blood volume regulation. *Anesth Analg* 2009;108:1922-8.
183. RABINSTEIN AA, WIJDICKS EF. Hyponatremia in critically ill neurological patients. *Neurologist* 2003;9:290-300.
184. PALMER BF. Hyponatremia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion *versus* cerebral salt wasting. *Nephrol Dial Transplant* 2000;15:262-8.
185. BRIMIOULLE S, ORELLANA-JIMENEZ C, AMINIAN A, VINCENT JL. Hyponatremia in neurologic patients: cerebral salt wasting *versus* inappropriate antidiuretic hormone secretion. *Intensive Care Med* 2008;34:125-31.
186. SARAMMA PP, GIRISH MENON R, SRIVASTAVA A, SANKARA SARMA P. Hyponatremia after aneurysmal subarachnoid hemorrhage: implications and outcomes. *J Neurosci Rural Pract* 2013;4(1):24-8.
187. MORI T, KATAYAMA Y, KAWAMATA T, HIRAYAMA T. Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1999; 91:947-52.

188. WOO MH, KALE-PRADHAN PB. Fludrocortisone in the treatment of subarachnoid hemorrhage-induced hyponatremia. *Ann Pharmacother* 1997;31:637-9.
189. MORON, KATAYAMA Y, KOJIMA J, MORI T, KAWAMATA T. Prophylactic management of excessive natriuresis with hydrocortisone for efficient hypervolemic therapy after subarachnoid hemorrhage. *Stroke* 2003;34:2807-11.
190. KATAYAMA Y, HARAOKA J, HIRABAYASHI H, *et al.* A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. *Stroke* 2007;38:2373-5.
191. SUAREZ JI, QURESHI AI, PAREKH PD, *et al.* Administration of hypertonic (3%) sodium chloride/acetate in hyponatremic patients with symptomatic vasospasm following subarachnoid hemorrhage. *J Neurosurg Anesthesiol* 1999;11:178-84.

Sažetak

PREPORUKE ZA LIJEČENJE KOMPLIKACIJA U BOLESNIKA NAKON ANEURIZMATSKOG SUBARAHNOIDNOG KRVARENJA

Predstavljamo smjernice za liječenje komplikacija u bolesnika nakon aneurizmatškog subarahnoidnog krvarenja temeljene na dokazima, a prihvaćene od strane Hrvatskoga društva za neurovaskularne poremećaje, Hrvatskoga društva za neurologiju uključivo i Sekciju za intenzivnu neurologiju, Hrvatskoga društva za neurokirurgiju, Hrvatskoga društva za zbrinjavanje otežanog dišnog puta i Hrvatskoga liječničkog zbora. Sastoje se od preporuka za zbrinjavanje, praćenje i liječenje bolesnika nakon aneurizmatškog subarahnoidnog krvarenja, temeljenih na dostupnoj literaturi, rezultatima velikih međunarodnih kliničkih ispitivanja i kolektivnog iskustva autora.

Ključne riječi: *Subarahnoidno krvarenje; Aneurizma; Komplikacije; Terapija lijekovima; Praktična smjernica*

GENERAL RECOMMENDATIONS FOR THE MANAGEMENT OF ANEURYSMAL SUBARACHNOID HEMORRHAGE

Vesna Vargek Solter¹, Tomislav Breitenfeld¹, Marina Roje-Bedeković¹, Višnja Supanc¹,
Arijana Lovrenčić-Huzjan¹, Vesna Šerić¹, Igor Antončić², Silvio Bašić³, Vili Beroš⁴, Ivan Bielen⁵,
Silva Butković Soldo⁶, Dragutin Kadojić⁶, Ivo Lušić⁷, Branka Maldini⁸, Anton Marović⁷, Josip Paladino⁹,
Zdravka Poljaković¹⁰, Branko Radanović⁶, Marko Radoš¹¹, Krešimir Rotim⁴, Miroslav Vukić⁹,
Dijana Zadravec¹², Vanja Bašić Kes¹

¹University Department of Neurology, Sestre milosrdnice University Hospital Center, Zagreb

²University Department of Neurology, Rijeka University Hospital Center, Rijeka

³University Department of Neurology, Dubrava University Hospital, Zagreb

⁴University Department of Neurosurgery, Sestre milosrdnice University Hospital Center, Zagreb

⁵University Department of Neurology, Sveti Duh University Hospital, Zagreb

⁶University Department of Neurology, Osijek University Hospital Center, Osijek

⁷University Department of Neurology, Split University Hospital Center, Split

⁸University Department of Anesthesiology, Resuscitation and Intensive Medicine, Sestre milosrdnice University Hospital Center, Zagreb

⁹University Department of Neurosurgery, Zagreb University Hospital Center, Zagreb

¹⁰University Department of Neurology, Zagreb University Hospital Center, Zagreb

¹¹University Department of Diagnostic and Interventional Radiology, Zagreb University Hospital Center, Zagreb

¹²University Department of Diagnostic and Interventional Radiology, Sestre milosrdnice University Hospital Center, Zagreb

SUMMARY – Subarachnoid hemorrhage is a neurologic emergency and a detrimental cerebrovascular event with a high rate of death and complications. Recommendations have been developed and based on literature search, evaluation of the results of large international clinical trials, collective experience of the authors, and endorsed by the Croatian Society of Neurovascular Disorders, Croatian Society of Neurology including Section for Neurocritical Care, Croatian Neurosurgical Society, Croatian Society for Difficult Airway Management and Croatian Medical Association. The aim of these guidelines is to provide current and comprehensive recommendations and to assist physicians in making appropriate decisions in the management of subarachnoid hemorrhage. Evidence based information on the epidemiology, risk factors and prognosis, as well as recommendations on diagnostic work up, monitoring and management are provided, with regard to treatment possibilities in Croatia.

Key words: *Subarachnoid hemorrhage – diagnosis; Aneurysm – diagnosis; Subarachnoid hemorrhage – therapy; Aneurysm – therapy; Practice guideline*

Correspondence to: *Assist. Prof. Tomislav Breitenfeld, MD, PhD*, University Department of Neurology, Sestre milosrdnice University Hospital Center, Vinogradska c. 29, HR-10000 Zagreb, Croatia
E-mail: tomislav.breitenfeld@zg.t-com.hr

Subarachnoid hemorrhage (SAH) is a neurologic emergency and a cerebrovascular event with frequent devastating effects on the central nervous system, possible secondary brain injury due to delayed cerebral ischemia and common systemic manifestations affecting cardiovascular, renal and pulmonary function. SAH is a significant cause of morbidity and mortality throughout the world, which makes it a relevant health problem. It occurs with an incidence of 2 to 20 cases *per* 100,000 individuals. It varies from region to region and the aggregate worldwide incidence is about 10 cases *per* 100,000¹. It accounts for 2 to 5 percent of all new strokes. The prognosis is influenced by multiple non-modifiable factors and by factors that can be influenced by therapeutic interventions and management procedures. Current developments in neurocritical care have improved the level of care and clinical outcome, however, the lack of high quality data has led to numerous approaches to management and limited guidance on choosing among them. Recent international guidelines are available in the United States of America from the Neurocritical Care Society² and American Heart Association/American Stroke Association³, and in the European Union from the European Stroke Organisation⁴. Due to some differences in the epidemiology and technical diagnostic and management specificities, it turned out pragmatically to publish recommendations from the Croatian standpoint.

Definitions of Classes and Levels of Evidence Used in Recommendations

- Class I Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and effective.
- Class II Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
- Class IIa The weight of evidence or opinion is in favor of the procedure or treatment.
- Class IIb Usefulness/efficacy is less well established by evidence or opinion.
- Class III Conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful.

Therapeutic recommendations

Level of Evidence A Data derived from multiple randomized clinical trials or meta-analyses.

Level of Evidence B Data derived from a single randomized trial or nonrandomized studies.

Level of Evidence C Consensus opinion of experts, case studies, or standard of care.

Diagnostic recommendations

Level of Evidence A Data derived from multiple prospective cohort studies using a reference standard applied by a masked evaluator.

Level of Evidence B Data derived from a single grade A study, or ≥ 1 case-control studies, or studies using a reference standard applied by an unmasked evaluator.

Level of Evidence C Consensus opinion of experts.

Risk Factors

Risk factors can be divided into risk factors for SAH (non-modifiable risk factors: sex, age, size of aneurysm and family history, and modifiable: cigarette smoking, hypertension and excessive alcohol intake), risk factors for aneurysm formation (female sex, current cigarette smoking, hypertension, age at diagnosis and family history) and risk factors for aneurysm growth (current cigarette smoking).

The incidence in women is 1.24 times higher than in men⁵. Evidence of a sex-age effect on SAH incidence has emerged from pooled study data, with a higher incidence reported in younger men (25-45 years of age), women between 55 and 85 years of age, and men >85 years of age^{5,6}.

An important but non-modifiable risk factor is familial predisposition to SAH. Between 5% and 20% of patients with SAH have a positive family history⁷. First-degree relatives of patients with SAH have a 3- to 7-fold increased risk of being struck by the same disease⁸⁻¹³. In second-degree relatives, the incidence of SAH is similar to that found in the general population⁸. Also, many studies show that around 10% of patients with SAH have a family history. The chance

of finding an aneurysm at screening is around 10% if two or more first-degree relatives are affected⁸⁻¹⁰. Two large observational studies of familial aneurysms suggest that screening these patients may also be cost-effective in preventing aneurysmal SAH (aSAH) and improving the quality of life^{14,15}.

The occurrence of SAH is also associated with specific heritable disorders of connective tissue, but these patients account for only a minority of all patients with SAH. Even though autosomal dominant polycystic kidney disease (ADPKD) is the most common heritable disorder associated with SAH, it is found in only 2% of all patients with SAH^{16,17}. Other genetically determined disorders that have been associated with SAH are Ehlers-Danlos disease type IV and neurofibromatosis type 1, but these associations are weaker than between ADPKD and aneurysms and these syndromes are seldom found in patients with SAH¹⁷⁻¹⁹.

The major identified modifiable risk factors include cigarette smoking, hypertension, alcohol abuse and use of sympathomimetic drugs (e.g., cocaine)³. Cigarette smoking is an independent and the most important risk factor for SAH, aneurysm formation, growth and rupture⁴. In developed countries of western hemisphere, the prevalence of smoking in SAH patients is 45%-75% (in general adult population 20%-35%), in addition 40% of all SAH patients can be attributed to cigarette smoking²⁰⁻²⁵. The prevalence of hypertension among SAH patients (20%-45%) is somewhat higher than in the general population. Even though the data regarding the relationship between hypertension and SAH are somewhat conflicting, hypertension can be considered to be an important risk factor for SAH and possibly for aneurysm formation and fatal aneurysm rupture²⁰⁻²⁴. Alcohol abuse and particularly sudden intake of high quantities is a risk factor for aneurysm rupture and should be desisted²⁰⁻²⁵. However, despite marked improvements in the treatment of hypertension and hyperlipidemia and the decrease in the rates of smoking over time, the incidence of SAH has not changed appreciably in the last 30 years²⁶. Further on, greater vegetable consumption is associated with a lower risk of stroke and SAH²⁷. Higher coffee and tea consumption²⁸ and higher magnesium consumption²⁹ were associated with a reduced risk of stroke overall, but did not change the risk of SAH.

The risk of growth and aneurysm rupture remains disputable, quite depending on the size and location of the aneurysm^{30,31}. According to an international study of unruptured intracranial aneurysms³⁰, in patients with no history of SAH, the five-year cumulative rate of rupture of aneurysms located in the internal carotid artery, anterior communicating artery, anterior cerebral artery, or middle cerebral artery is zero for aneurysms under 7 mm, 2.6% for 7 to 12 mm, 14.5% for 13 to 24 mm, and 40% for 25 mm or more. This rate is in contrast to rupture rates of 2.5%, 14.5%, 18.4% and 50%, respectively, for the same sizes of aneurysms in the posterior circulating and posterior communicating artery³². In addition, when followed up on magnetic resonance imaging (MRI), aneurysms ≥ 8 mm tended to grow more over time³³, which implies a higher risk of rupture. Several characteristics of aneurysm morphology such as a bottleneck shape³⁴ and the aneurysm size to parent vessel ratio^{35,36} have been associated with rupture status, but how these might be applied to individual patients to predict future aneurysmal rupture is still unclear. In addition to the mentioned international study of unruptured intracranial aneurysms³⁰, new findings suggest that the risk of first episodes of rupture of aneurysms under 7 mm in anterior cerebral circulation does exist, although slightly lower than 1%³⁷.

Patients with adequately obliterated aneurysms after aSAH have a low risk of recurrent aSAH for at least 5 years³⁸, although some coiled aneurysms require retreatment³⁹.

Risk factor recommendations

1. High blood pressure is an important risk factor, so hypertension treatment may reduce the risk of aSAH (Class I; Level of Evidence B).
2. Cigarette smoking and alcohol abuse should be ceased in order to reduce the risk of aSAH³ (Class I; Level of Evidence B).
3. The risk of aneurysm rupture might be evaluated considering its size, location and morphological and hemodynamic characteristics, together with the patient's age and health status³ (Class IIb; Level of Evidence B).
4. Noninvasive screening is reasonable to be considered when two or more first-degree relatives are affected (Class IIb; Level of Evidence B).

Clinical Presentation and Diagnosis

Although headache is a common presenting chief complaint in the emergency department, and aSAH accounts for only 1% of all headaches evaluated in the emergency department, it should always be suspected in patients with a typical presentation, one of the most pathognomonic pictures in all of clinical medicine⁴⁰.

The central feature of classic aSAH is sudden onset of severe headache, approximately 80% of patients describe the pain as "the worst headache of my life"⁴¹. Any patient's first or worst headache should suggest aSAH and prompt ordering of head computed tomography (CT) scan. In more than 20% of patients, less severe hemorrhages may cause headache of moderate intensity, neck pain, and nonspecific symptoms. Headache is often accompanied with nausea, vomiting, neck stiffness and back pain, photophobia, loss of consciousness, seizures or focal neurological deficits (including cranial nerve palsies).

Despite the classic presentation, aSAH is misdiagnosed in approximately 12% of cases. The common incorrect diagnoses are migraine and tension-type headaches. The most common diagnostic error is failure to obtain a noncontrast head CT scan^{42,43}.

Prodromal events in the form of sentinel or warning leaks, with minor loss of blood from the aneurysm before a major rupture, are reported to occur in 30%-50% of aSAH and precede overt aSAH by 2 to 8 weeks^{44,45}. Sentinel leaks produce sudden focal or generalized head pain that may be severe. In addition to headaches, sentinel leaks may produce nausea, vomiting, photophobia or, less commonly, neck pain. These symptoms may be ignored by the physician. Therefore, a high index of suspicion is necessary because diagnosis of the warning leak or sentinel hemorrhage before a catastrophic rupture may be lifesaving⁴⁶. Sentinel leaks usually do not generate symptoms suggestive of elevated intracranial pressure (ICP) or meningeal irritation and they usually do not occur in patients with arteriovenous malformations. Prodromal presentations occasionally are also caused by the mass effect of an expanding aneurysm and have characteristic features based on aneurysm location.

The clinical condition upon admission of a patient is most commonly rated with the Glasgow Coma Scale (GCS)⁴⁷, Hunt and Hess Scale (HHS)⁴⁸ or the

World Federation of Neurological Surgeons Scale (WFNS)⁴⁹. Obtaining a score with either HHS or WFNS on admission is recommended, as this is the single most useful predictor of long-term outcome³.

Since subarachnoid blood is almost always detectable on CT scans on the first day of aSAH, with its typical distribution in the subarachnoid space/basal cisterns, noncontrast CT remains the single most important test for the diagnosis of aSAH³. Therefore, if aSAH is clinically suspected, cranial CT should be performed to confirm the diagnosis⁴. In the first 24 hours, the sensitivity of CT for SAH is 92%-95%⁵⁰⁻⁵⁵. With the newer generation of CT scanners, the sensitivity reaches 97%-100% within the first 6 h and 87% at 6 h or more after symptom onset⁵³. The sensitivity to detect blood on head CT declines to 57%-85% on days 5 and 6 and declines to 50% after 1 week^{52,56}. Fisher scale is a radiological scale based on the amount and distribution of blood on CT. The score corresponds to the likelihood of delayed cerebral ischemia (DCI) to occur⁵⁷.

Advances in MRI of the brain⁵⁸⁻⁶⁰ can often allow the diagnosis of aSAH to be made when head CT scan is negative and there is clinical suspicion of aSAH, possibly avoiding the need of lumbar puncture.

However, in case of history or clinically suspected SAH, despite negative/inconspicuous CT and/or MRI scans, lumbar puncture should be performed^{3,4}.

The usefulness of MRI and MR angiography (MRA) in the acute setting is often limited by logistics, the need of acute resuscitation and critical care management of the patient and motion artifacts³. Computed tomographic angiography (CTA) is more readily obtainable and faster than MRA. This imaging modality carries a sensitivity of 77%-100% for all aneurysms and 95%-100% for aneurysms ≥ 5 mm. However, aneurysms < 3 mm in size continue to be unreliably demonstrated on CTA^{61,62}. In cases of perimesencephalic SAH, the role of CTA is still controversial; it remains unclear whether a negative CTA result is sufficient to rule out aneurysmal hemorrhage and that cerebral angiography is not required^{63,64}.

Digital subtraction angiography (DSA) was indicated if there was a diffuse aneurysmal pattern of aSAH, and repeat delayed DSA was required if the initial DSA findings were negative, which led to the

detection of a small aneurysm in 14% of cases. So, despite the presence of less invasive methods (MRA and CTA), cerebral panangiography (DSA) continues to be the gold standard for detection, demonstration and localization of ruptured aneurysms⁴. The rate of complications associated with this invasive diagnostic procedure is below 0.5% in experienced centers⁶⁵.

Clinical presentation and diagnosis recommendations

1. aSAH is a medical emergency typically presented with sudden onset of severe headache, however, frequently misdiagnosed³ (Class I; Level of Evidence B).
2. As the most useful indicator of outcome after aSAH, the simple validated scales (e.g., Hunt and Hess, World Federation of Neurological Surgeons) should be used for rapid determination of the initial clinical severity of aSAH³ (Class I; Level of Evidence B).
3. The risk of early aneurysm rebleeding is high, and rebleeding is associated with very poor outcomes. Therefore, urgent evaluation and treatment of patients with suspected aSAH is recommended³ (Class I; Level of Evidence B).
4. Acute diagnostic workup should include noncontrast head CT, which, if nondiagnostic, should be followed by lumbar puncture³ (Class I; Level of Evidence B).
5. CT/CTA and multisequential MRI/MRA are equally suitable for the diagnosis of SAH within 24 h and may confirm the underlying cause⁴ (Class II; Level of Evidence B).
6. CTA may be considered in the workup of aSAH. If an aneurysm is detected by CTA, this study may help guide the decision on the type of aneurysm repair, but if CTA is inconclusive, DSA is still recommended (except possibly in the instance of classic perimesencephalic aSAH)³ (Class IIb; Level of Evidence C).
7. MRI (fluid-attenuated inversion recovery, proton density, diffusion-weighted imaging, and gradient echo sequences) may be reasonable for the diagnosis of aSAH in patients with a nondiagnostic CT scan, although a negative result does not obviate the need of cerebrospinal fluid analysis³ (Class IIb; Level of Evidence C).
8. DSA is indicated for detection of aneurysm in patients with aSAH (except when the aneurysm was previously diagnosed by noninvasive angiogram) and for planning treatment (to determine whether the aneurysm is suitable to coiling or to expedite microsurgery)³ (Class I; Level of Evidence B).
9. If no aneurysm was found, in patients with non-perimesencephalic SAH (with typical pattern of SAH) CTA or DSA should be repeated not earlier than 3 weeks after the initial bleeding, if there are no other therapeutic indications to perform imaging studies earlier⁴ (Class II; Level of Evidence C).

Treatment

All patients with aSAH should be evaluated and treated on an emergency basis with maintenance of airway and cardiovascular function.

After initial stabilization, patients should be transferred to centers with neurovascular expertise and preferably with a dedicated neurological critical care unit to optimize care^{66,67}. The patients diagnosed with aSAH should be treated at high volume centers (>35 cases *per* year) with appropriate specialty neurointensive care units (NICUs), neurointensivists, vascular neurosurgeons and interventional neuroradiologists⁶⁸⁻⁷⁰.

Once in the (neuro)critical care setting, the main goal of treatment is primarily aneurysm repair together with the prevention of rebleeding, prevention and management of vasospasm, and treatment of other medical and neurological complications.

Staff in this unit should have ample experience in assessing swallowing function to prevent pneumonia, a frequent complication after SAH and an independent risk factor for poor outcome⁷¹.

Electrocardiography (ECG), level of consciousness (GCS), pupils, focal deficits and temperature should be monitored frequently for at least the first 7 days after aSAH, or longer as required depending on the patient's clinical condition⁴.

Elevated ICP is often associated with aSAH. It can be caused by hydrocephalus, space-occupying intracerebral hemorrhage (ICH), and global and focal cerebral edema. Hydrocephalus occurs in 20%-30% of patients after SAH⁷²⁻⁷⁴. The treatment of choice is insertion of an extraventricular drain (EVD)³, which may result in prompt clinical response such as im-

provement of consciousness⁷⁵. The risk of infection ranges from 2.2% to 21.9%, depending on the number of manipulations and sterile techniques used. If there is no improvement after 36–48 h and the ICP is low, a poor neurological state is likely due to primary brain injury related to the acute effects of hemorrhage. Weaning of the EVD should begin after ICP has been controlled for 48 h, either by trials of intermittent clamping or raising the EVD level with ICP monitoring. Craniotomy and surgical decompression is reasonable in space-occupying intraparenchymal hemorrhages. Decompressive craniectomy can be beneficial in patients with life-threatening cerebral edema with and without intracerebral hemorrhage, due to infarction or recurrent hemorrhage, and should be performed rapidly to avoid herniation⁷⁶.

In the intensive care unit, blood pressure (BP) is monitored continuously *via* an arterial line. Treatment of hypertension remains controversial. Data from observational studies suggest that aggressive treatment of BP may decrease the risk of rebleeding but at the cost of an increased risk of secondary ischemia⁷⁷. It seems reasonable, but without good evidence not to treat hypertension unless the BP is extreme. Limits for extreme BP should be set on individual basis, taking into account age of the patient, pre-SAH BP and cardiac history. Systolic BP should be kept below 160 mm Hg (for example, by means of esmolol or labetalol), only until coiling or clipping of ruptured aneurysm, to reduce the risk for rebleeding^{3,4}.

Regarding fluids and electrolytes, intravenous line is mandatory. A calculated fluid balance every 6 h during the initial week is advised in all patients, as well as urinary catheter. Normovolemia should be aimed⁴.

Headache pain should be treated initially with paracetamol (500 mg every 3–4 h). Salicylates are best avoided because their antihemostatic effect is unwanted in patients who may have to undergo external ventricular drainage and interferes with the possibly pending neurosurgical interventions. For severe pain, use of codeine and tramadol are reasonable, while synthetic opiate like piritramide might be considered only as the last resort⁴.

To avoid situations that increase ICP, the patient should be kept in bed and the application of antiemetic drugs, laxatives and analgesics should be considered before occlusion of the aneurysm⁴.

Hyperglycemia develops in one-third of SAH patients. Hyperglycemia is associated with poor clinical condition on admission, and is independently associated with poor outcome^{78–81}.

Regarding thromboprophylaxis, in a placebo-controlled trial of enoxaparin (a low-molecular-weight heparin, LMWH) administered subcutaneously 40 mg once a day after surgical aneurysm occlusion, intracranial bleeding complications occurred somewhat more often in the enoxaparin group, while there was no overall influence on outcome or occurrence of post-SAH cerebral infarction^{82,83}. Enoxaparin also increased the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors⁸⁴. Because of this increased risk of intracranial bleeding from thromboprophylaxis by means of LMWH, the use of stockings or pneumatic devices seems more appropriate in SAH patients. A study with nonrandomized controls has suggested that deep vein thrombosis can be successfully prevented by the use of pneumatic devices⁸⁵. A Cochrane review on the use of graduated compression stockings or intermittent pneumatic compression in patients with stroke did not find support for the use of either method⁸⁶. In a randomized trial in patients with ICH, the combination of stockings and intermittent pneumatic compression resulted in a smaller risk of deep venous thrombosis than prevention by stockings alone⁸⁷. This combination may be the preferred strategy because there is no reason to suppose that this effect would be any different in patients with SAH, but it needs further study.

Seizures at onset occur in around 7% of patients, but their impact on prognosis is uncertain⁸⁸. Another 10% develop seizures in the first few weeks⁸⁹, and convulsive status epilepticus occurs in 0.2%⁹⁰. In patients who are comatose, nonconvulsive status epilepticus has been detected in 8% of patients⁹¹, but the proportion in this study might be an overestimation due to selection of electroencephalography (EEG) by indication. Whether continuous EEG monitoring should be performed in all SAH patients or in the subset of comatose patients is an unresolved issue. An observational study performed in 3,552 patients participating in 4 prospective, randomized, double-blind, placebo-controlled trials suggested that the outcome was worse

in 65% of patients receiving prophylactic antiepileptic drugs than in the other 35% of patients who did not receive prophylactic antiepileptic medication⁹². Given the lack of evidence in favor of prophylactic treatment with antiepileptic drugs and the possible disadvantage of serious adverse drug reactions, current advice should be not to start antiepileptic drugs as prophylactic treatment.

The use of hydrocortisone in patients with SAH does not improve clinical outcome but it doubles the risk of hyperglycemia⁴.

Patients in a good clinical condition in whom the aneurysm has been secured can be transferred to a regular care bed in the stroke unit⁴.

Treatment recommendations

1. To avoid situations that increase ICP, the patient should be kept in bed and the application of antiemetic drugs, laxatives and analgesics should be considered before occlusion of the aneurysm⁴ (Class IIa; Level of Evidence C).
2. Hyperglycemia over 10 mmol/L should be treated⁴ (Class IIa; Level of Evidence C).
3. Increased temperature should be treated medically and physically⁴ (Class IIa; Level of Evidence C).
4. Until coiling or clipping, systolic BP should be kept below 160 mm Hg³ (Class IIa; Level of Evidence C). If systolic pressure remains high despite these treatments, further lowering of BP should be considered⁴ (Class III; Level of Evidence C). If BP is lowered, the mean arterial pressure should be kept at least above 90 mm Hg⁴ (Class IIa; Level of Evidence C).
5. Patients with SAH may be given thromboprophylaxis with pneumatic devices and/or compression stockings before occlusion of the aneurysm. In case deep vein thrombosis prevention is indicated, LMWH should be applied not earlier than 12 h after surgical occlusion of the aneurysm and immediately after coiling⁴ (Class II; Level of Evidence B).
6. Antiepileptic treatment should be administered in patients with clinically apparent seizures⁴ (Class IIa; Level of Evidence C). There is no evidence that supports the prophylactic use of antiepileptic drugs⁴ (Class III; Level of Evidence C).
7. There is no proof that steroids are effective in patients with SAH⁴ (Class III; Level of Evidence C).

Aneurysm Repair

Currently, the two main therapeutic options for securing a ruptured aneurysm are microvascular neurosurgical clipping and endovascular coiling. Historically, microsurgical clipping has been the preferred method of treatment. Although the timing of surgery has been debated, most neurovascular surgeons recommend early operation. Evidence from clinical trials suggest that patients undergoing early surgery have a lower rate of rebleeding and tend to fare better than those treated later⁹³. Securing the ruptured aneurysm will also facilitate the treatment of complications such as cerebral vasospasm. Although many neurovascular surgeons use mild hypothermia during microsurgical clipping of aneurysms, it has not proved to be beneficial in patients with lower grades of SAH⁹⁴.

In the early beginnings of cerebral aneurysm treatment, surgery was the only approach in aneurysm repair. Since the development of aneurysm clips, the risk of rebleeding has significantly decreased. With the establishment of microsurgery, surgical approaches have become smaller and less traumatizing. Furthermore, intraoperative indocyanine green angiography and Doppler sonography lead to extra intraoperative quality control.

After the invention of detectable platinum coils by G. Guglielmi in 1990, an alternative to surgical clipping has been developed⁹⁵. Endovascular treatment of aneurysms has been available as an alternative to surgical therapy for more than 20 years now. Coils are made of platinum and are attached to a delivery wire. Once proper position within the aneurysm is achieved, coils are detached from the wire. Multiple coils of various length and diameter are often packed into the aneurysm to exclude it from the circulation. The International Subarachnoid Aneurysm Trial (ISAT) was a landmark study that validated the technique of endovascular coiling^{96,97}.

With advancements in both microsurgical and endovascular approaches, algorithms to determine the proper patient population and aneurysmal characteristics for each treatment are continually undergoing refinement.

Timing of aneurysm repair

Up to 15% of patients rebleed during the first few hours after the initial hemorrhage, that is, during transportation or before the treatment team is able to occlude the aneurysm. Patients surviving the first day after the initial aSAH have a cumulative risk of 35%-40% to suffer rebleeding of the aneurysm with a mortality rate of about 40%. After 4 weeks, the risk of rebleeding decreases to about 3%/year⁹⁸. The primary goal of aSAH treatment is occlusion of the ruptured aneurysm, i.e. to close the bleeding source preventing rebleeding. As mentioned, two major treatment options are available: neurosurgical clipping and endovascular coiling. A meta-analysis of 11 out of 268 studies with a total of 1,814 patients revealed in a comparative evaluation of early *versus* late surgical clipping of ruptured aneurysms that early treatment (within 72 h after SAH) of patients with a good clinical/neurological condition on admission (WFNS 1-3) led to a significantly better outcome. A similar trend, without statistical significance, could be detected in patients with worse WFNS grades 4-5⁹⁹. Even earlier treatment (within 12 h) of SAH patients with WFNS grades IV and V did not increase the number of dependent survivors¹⁰⁰. Although there are no good evidence-based data, a general long-lasting consensus exists that ruptured aneurysms of patients with good and moderate clinical SAH grades (WFNS 1-4; Hunt and Hess grade I-IV) should be treated in the early phase after the initial bleeding (<72 h after SAH). In patients presenting with multiple intracranial aneurysms, i.e. with one ruptured aneurysm causing SAH and several unruptured incidental aneurysms, the ruptured aneurysm is primarily treated. Subsequent treatment of the unruptured incidental aneurysms depends on the clinical course after SAH, outcome, age, size, location and configuration of the aneurysm.

Surgical clipping and endovascular coiling

The decision should be made by a team of neurological, neurosurgical and interventional cerebrovascular experts. ISAT was the only multicenter randomized trial comparing microsurgical and endovascular repair (clipping and coiling but without balloon or stent techniques)⁹⁷. The ISAT study followed the 'uncertainty principle'. The main inclusion criterion of ISAT was that a ruptured aneurysm seemed equally

accessible and treatable by either surgical clipping or endovascular coiling ('clinical equipoise'). This inclusion criterion was met by 22.4% of patients (2,143 of 9,559 patients) treated during the study period at the study centers. The remaining 77.6% of patients suffered from aneurysms which were preferably treated by either coiling or clipping. Those patients were not randomized and were excluded from the study. Besides a highly selected patient cohort, ISAT was also criticized for its high (90%) proportion of patients with good clinical grades after SAH (Hunt and Hess grades 1-2) and underrepresentation of middle cerebral artery aneurysms, which are often anatomically more difficult to be coiled than aneurysms in other locations. However, for this subpopulation of ruptured aneurysms, which were equally coilable or clipable, ISAT showed that endovascular coiling had an advantage over surgical clipping, with better clinical outcome: absolute risk reduction of death and severe disability after 1 year was 6.9% in favor of coiling *versus* clipping, based on the observation that 23.7% of endovascular-treated patients (compared to 30.6% of patients after clipping) stayed severely disabled or died after 1 year⁹⁷. The 9-year follow-up of ISAT also revealed a reduction in the relative 5-year mortality risk in favor of coiling. No difference could be observed in the amount of independent SAH survivors between the clip (82%) and coil (83%) group. Both early and follow-up ISAT analysis showed that patients treated with coiling had a higher rebleeding risk, which was comparable to the risk of suffering SAH from a new aneurysm^{97,101}. The postoperative risk of rebleeding appears to be associated with the degree of insufficient aneurysm occlusion. Another follow-up study of the patients treated in the ISAT was performed to compare the frequency and consequences of aneurysm recurrence. Retreatment was performed in 17.4% of patients after primary endovascular coiling and in 3.8% of patients after neurosurgical clipping. Late retreatment was 6.9 times more likely after coiling. Younger age, larger lumen size, and incomplete occlusion were the risk factors for late retreatment after coiling¹⁰². A *post hoc* modeling study with mortality as outcome parameter only after coiling and clipping for patients from the ISAT emphasized that no advantage of coil embolization over clip ligation could be assumed for patients younger than 40 years. For these

patients, clipping might even be a better treatment option in terms of life expectancy^{103,104}. Because of the highly selected aneurysm subpopulation in ISAT, its results cannot be generalized.

Although in endovascular coiling, the complete obliteration rate can be increased by the addition of a high-porosity stent, this has been associated with an increased risk of complications, especially in patients with SAH, in large part because of the need of periprocedural dual-antiplatelet therapy to prevent arterial thromboembolism¹⁰⁵. Whether low-porosity flow-diverting stents with or without coils represent a better option for many or most of those presenting with SAH from saccular aneurysms, remains to be studied, but these stents make more conceptual sense for use in the patient with a dissecting aneurysm, in whom vessel sacrifice is not an option and microsurgical solutions carry a higher risk.

Recent advances in technique including the balloon remodeling technique that holds the coils in the aneurysm cavity, liquid polymer coils and embolic agents make treatment of broad neck aneurysm feasible.

Recent studies, which consider increasing endovascular treatment during the last years, could not detect any difference in mortality and morbidity between coiling and clipping¹⁰⁴. The main concern about endovascular therapy is an increased rate of rebleeding after several years due to coil compaction and aneurysm regrowth at the residual neck.

Given this delicate balance between safety and durability, there have been multiple efforts to identify subgroups of patients who might be best treated with endovascular or microsurgical techniques. The quality of data is modest. Summarizing current studies, ruptured aneurysms are complex lesions.

The primary goal of treatment should be complete occlusion of the aneurysm sack to reduce postprocedural rerupture and bleeding. In case of aneurysms which can be treated equally with clipping or coiling, without stent or balloon, endovascular therapy is preferred. However, indications and treatments should be discussed in an interdisciplinary dialogue. In case of an accompanying space occupying intracerebral hematoma, surgical treatment and clipping is preferred.

As a rough guidance, aneurysms with a wide neck, branching vessels out of the aneurysm sack, middle cerebral artery aneurysms or patients with intracere-

bral hematoma should preferably be treated by clipping, while aneurysms of the basilar artery or elderly patients (patients >70 years, small aneurysm neck, posterior circulation) should be coiled. Any decision concerning treatment should be interdisciplinary and based on the experience and treatment results of the neurosurgeon and endovascular radiologist together with cerebrovascular neurologist, and should be adapted to the individual aspects including parameters such as age, general state of health, location, configuration and size of the aneurysm, as well as the request of the patient. Patients with aSAH should be treated in centers that offer high-quality treatment with both modalities because the skills of the treating interventionalist or neurosurgeon, as well as the institution, may have great impact on outcome.

Treatment of ruptured aneurysm – surgical and endovascular methods: recommendations

1. Ruptured aneurysm should be treated as early as logistically and technically possible to reduce the risk of rebleeding after aSAH; if possible, it should be aimed to intervene at least within 72 h after onset of first symptoms⁴ (Class I; Level of Evidence B). The decision should not depend on grading⁴ (Class IIb; Level of Evidence C).
2. Complete obliteration of the aneurysm is recommended³ (Class I; Level of Evidence B).
3. The decision for the best mode of aneurysm treatment, as judged by experienced cerebrovascular neurologists, cerebrovascular surgeons and endovascular specialists, should be multidisciplinary and based on characteristics of the patient and the aneurysm, and the patient should be informed and included in the process of decision making^{3,4} (Class I; Level of Evidence C).
4. In general, the decision on whether to clip or coil depends on several factors related to 3 major components: (1) Patient: age, comorbidity, presence of ICH, SAH grade, aneurysm size, location and configuration, as well as the status of collaterals; (2) Procedure: competence, technical skills and availability; and (3) Logistics: the grade of interdisciplinarity⁴ (Class IIb, Level of Evidence B).
5. Factors in favor of operative intervention (clipping) in patients with aSAH are: younger age,

presence of space occupying ICH and aneurysm-specific factors such as location (middle cerebral artery and pericallosal aneurysm), wide aneurysm neck and arterial branches exiting directly out of the aneurysmal sack (Class IIb, Level of Evidence B), or other unfavorable vascular and aneurysmal configuration for coiling⁴.

6. Factors in favor of endovascular intervention (coiling) in patients with aSAH are: age above 70 years, patients presenting with poor-grade (World Federation of Neurological Surgeons classification IV/V) aSAH, space occupying ICH not present, and aneurysm-specific factors such as posterior location, small aneurysm neck, unilobar shape⁴ (Class IIb, Level of Evidence B).
7. For patients with ruptured aneurysms judged to be technically amenable to both endovascular coiling and neurosurgical clipping, endovascular coiling should be considered³ (Class I; Level of Evidence B).
8. In the absence of a compelling contraindication, patients who undergo coiling or clipping of a ruptured aneurysm should have delayed follow-up vascular imaging (timing and modality to be individualized), and strong consideration should be given to retreatment, either by repeat coiling or microsurgical clipping, if there is a clinically significant (e.g., growing) remnant³ (Class I; Level of Evidence B).
9. Stenting of a ruptured aneurysm is associated with increased morbidity and mortality, and should only be considered when less risky options have been excluded³ (Class III; Level of Evidence C).

References

1. INGALL T, ASPLUND K, MAHONEN M, BONITA R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. *Stroke* 2000;31:1054-61.
2. DIRINGER MN, BLECK TP, CLAUDE HEMPHILL J 3rd, MENON D, SHUTTER L, VESPA P, BRUDER N, CONNOLLY ES Jr, CITERIO G, GRESS D, HÄNGGI D, HOH BL, LANZINO G, Le ROUX P, RABINSTEIN A, SCHMUTZHARD E, STOCCHETTI N, SUAREZ JI, TREGGIARI M, TSENG MY, VERGOUWEN MD, WOLF S, ZIPFEL G. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference, Neurocritical Care Society. *Neurocrit Care* 2011;15(2):211-40.
3. CONNOLLY ES Jr, RABINSTEIN AA, CARHUAPOMA JR, DERDEYN CP, DION J, HIGASHIDA RT, HOH BL, KIRKNESS CJ, NAIDECH AM, OGILVY CS, PATEL AB, THOMPSON BG, VESPA P; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2012;43(6):1711-37.
4. STEINER T, JUVELA S, UNTERBERG A, JUNG C, FORSTING M, RINKEL G. European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid Haemorrhage. *Cerebrovasc Dis* 2013;35(2):93-112.
5. de ROOIJ NK, LINN FH, van der PLAS JA, ALGRA A, RINKEL GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. *J Neurol Neurosurg Psychiatry* 2007;78:1365-72.
6. EDEN SV, MEURER WJ, SANCHEZ BN, LISABETH LD, SMITH MA, BROWN DL, MORGENSTERN LB. Gender and ethnic differences in subarachnoid hemorrhage. *Neurology* 2008;71:731-5.
7. SCHIEVINK WI. Genetics of intracranial aneurysms. [Review]. *Neurosurgery* 1997;40:651-62.
8. BROMBERG JEC, RINKEL GJE, ALGRA A, GREEBE P, van DUYN CM, HASAN D, et al. Subarachnoid haemorrhage in first and second degree relatives of patients with subarachnoid haemorrhage. *BMJ* 1995;311:288-9.
9. SCHIEVINK WI, SCHAID DJ, MICHELS VV, PIEPGRAS DG. Familial aneurysmal subarachnoid hemorrhage: a community-based study. *J Neurosurg* 1995;83:426-9.
10. BOR AS, RINKEL GJ, ADAMI J, KOFFIJBERG H, EKBOM A, BUSKENS E, BLOMQVIST P, GRANATH F. Risk of subarachnoid haemorrhage according to number of affected relatives: a population based case-control study. *Brain* 2008;131:2662-5.
11. WANG PS, LONGSTRETH WT Jr, KOEPEL TD. Subarachnoid hemorrhage and family history. A population-based case-control study. *Arch Neurol* 1995;52:202-4.
12. De BRAEKELEER M, PERUSSE L, CANTIN L, BOUCHARD JM, MATHIEU J. A study of inbreeding and kinship in intracranial aneurysms in the Saguenay Lac-Saint-Jean region (Quebec, Canada). *Ann Hum Genet* 1996;60:99-104.
13. GAIST D, VAETH M, TSIROPOULOS I, CHRISTENSEN K, CORDER E, OLSEN J, et al. Risk of subarachnoid haemorrhage in first degree relatives of patients with

- subarachnoid haemorrhage: follow up study based on national registries in Denmark. *BMJ* 2000;320:141-5.
14. BOR AS, KOFFIJBERG H, WERMER MJ, RINKEL GJ. Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness analysis. *Neurology* 2010;74:1671-9.
 15. BRODERICK JP, BROWN RD Jr, SAUERBECK L, HORNUNG R, HUSTON J 3rd, WOO D, ANDERSON C, ROULEAU G, KLEINDORFER D, FLAHERTY ML, MEISSNER I, FOROUD T, MOOMAW EC, CONNOLLY ES; FIA Study Investigators. Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. *Stroke* 2009;40:1952-7.
 16. SCHIEVINK WI, TORRES VE, PIEPGRAS DG, WIEBERS DO. Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 1992; 3:88-95.
 17. WIEBERS DO, WHISNANT JP, HUSTON J 3rd, MEISSNER I, BROWN RD Jr, PIEPGRAS DG, FORBES GS, THIELEN K, NICHOLS D, O'FALLON WM, PEACOCK J, JAEGER L, KASSELL NF, KONGABLE-BECKMAN GL, TORNER JC. International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. *Lancet* 2003; 362:103-10.
 18. SCHIEVINK WI, MICHELS VV, PIEPGRAS DG. Neurovascular manifestations of heritable connective tissue disorders. A review. [Review]. *Stroke* 1994;25:889-903.
 19. PEPIN M, SCHWARZE U, SUPERTI-FURGA A, BYERS PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. *N Engl J Med* 2000;342:673-80.
 20. FEIGIN VL, RINKEL GJ, LAWES CM, ALGRA A, BENNETT DA, van GIJN J, ANDERSON CS. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. *Stroke* 2005;36:2773-80.
 21. KISSELA BM, SAUERBECK L, WOO D, KHOURY J, CARROZZELLA J, PANCIOLI A, JAUCH E, MOOMAW CJ, SHUKLA R, GEBEL J, FONTAINE R, BRODERICK J. Subarachnoid hemorrhage: a preventable disease with a heritable component. *Stroke* 2002;33:1321-6.
 22. JUVELA S, HILLBOM M, NUMMINEN H, KOSKINEN P. Cigarette smoking and alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. *Stroke* 1993;24:639-46.
 23. BONITA R. Cigarette smoking, hypertension and the risk of subarachnoid hemorrhage: a population-based case-control study. *Stroke* 1986;17:831-5.
 24. LONGSTRETH WT Jr, NELSON LM, KOEPEL TD, van BELLE G. Cigarette smoking, alcohol use, and subarachnoid hemorrhage. *Stroke* 1992;23:1242-9.
 25. RUIGROK YM, BUSKENS E, RINKEL GJ. Attributable risk of common and rare determinants of subarachnoid hemorrhage. *Stroke* 2001;32:1173-5.
 26. LOVELOCK CE, RINKEL GJ, ROTHWELL PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. *Neurology* 2010;74:1494-501.
 27. LARSSON SC, MÄNNISTÖ S, VIRTANEN MJ, KONTTO J, ALBANES D, VIRTAMO J. Dietary fiber and fiber-rich food intake in relation to risk of stroke in male smokers. *Eur J Clin Nutr* 2009;63:1016-24.
 28. LARSSON SC, MÄNNISTÖ S, VIRTANEN MJ, KONTTO J, ALBANES D, VIRTAMO J. Coffee and tea consumption and risk of stroke subtypes in male smokers. *Stroke* 2008;39:1681-7.
 29. LARSSON SC, VIRTANEN MJ, MARS M, MÄNNISTÖ S, PIETINEN P, ALBANES D, VIRTAMO J. Magnesium, calcium, potassium, and sodium intakes and risk of stroke in male smokers. *Arch Intern Med* 2008;168:459-65.
 30. WIEBERS DO, WHISNANT JP, HUSTON J III, *et al.* Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. *Lancet* 2003;362:103-10.
 31. WHITE PM, WARDLAW J. Unruptured intracranial aneurysms: prospective data have arrived. *Lancet* 2003;362:90-1.
 32. SUAREZ JI, TARR RW, SELMAN WR. Aneurysmal subarachnoid hemorrhage. *N Engl J Med* 2006;354:387-96.
 33. BURNS JD, HUSTON J 3rd, LAYTON KF, PIEPGRAS DG, BROWN RD Jr. Intracranial aneurysm enlargement on serial magnetic resonance angiography: frequency and risk factors. *Stroke* 2009;40:406-11.
 34. HOH BL, SISTROM CL, FIRMENT CS, FAUTHEREE GL, VELAT GJ, WHITING JH, REAVEY-CANTWELL JF, LEWIS SB. Bottleneck factor and height-width ratio: association with ruptured aneurysms in patients with multiple cerebral aneurysms. *Neurosurgery* 2007;61:716-22.
 35. DHAR SBE, TREMMEL M, MOCCO J, KIM M, YAMAMOTO J, SIDDIQUI AH, HOPKINS LNM, MENG H. Morphology parameters for intracranial aneurysm rupture risk assessment. *Neurosurgery* 2008;63:185-97.
 36. RAHMAN M, SMIETANA J, HAUCK E, HOH B, HOPKINS N, SIDDIQUI A, LEVY EI, MENG H, MOCCO J. Size ratio correlates with intracranial aneurysm rupture status: a prospective study. *Stroke* 2010;41:916-20.
 37. JUVELA S, PUSSA K, LEHTO H, PORRAS M. Natural history of unruptured intracranial aneurysms: a long-term follow-up study. *Stroke* 2013;44:2414-21.
 38. MOLYNEUX AJ, KERR RS, BIRKS J, RAMZI N, YARNOLD J, SNEADE M, RISCHMILLER J; ISAT Collaborators. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. *Lancet Neurol* 2009;8:427-33.

39. WILLINSKY RA, PELTZ J, da COSTA L, AGID R, FARB RI, BRUGGE KG. Clinical and angiographic follow-up of ruptured intracranial aneurysms treated with endovascular embolization. *AJNR Am J Neuroradiol* 2009;30:1035-40.
40. EDLOW JA. Diagnosing headache in the emergency department: what is more important? Being right, or not being wrong? *Eur J Neurol* 2008;15:1257-8.
41. BASSI P, BANDERA R, LOIERO M, TOGNONI G, MANGONI A. Warning signs in subarachnoid hemorrhage: a cooperative study. *Acta Neurol Scand* 1991;84:277-81.
42. van GIJN J, RINKEL GJ. Subarachnoid haemorrhage: diagnosis, causes and management. *Brain* 2001;124(Pt 2):249-78.
43. KOWALSKI RG, CLAASSEN J, KREITER KT, et al. Initial misdiagnosis and outcome after subarachnoid hemorrhage. *JAMA* 2004;291:866-9.
44. de FALCO FA. Sentinel headache. *Neurol Sci* 2004;25(Suppl 3):S215-S217.
45. POLMEAR A. Sentinel headaches in aneurysmal subarachnoid haemorrhage: what is the true incidence? A systematic review. *Cephalalgia* 2003;23:935-41.
46. JAKOBSSON KE, SÄVELAND H, HILLMAN J, EDNER G, ZYGMUNT S, BRANDT L, PELLETTIERI L. Warning leak and management outcome in aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1996;85:995-9.
47. TEASDALE G, JENNETT B. Assessment of coma and impaired consciousness. A practical scale. *Lancet* 1974;2(7872):81-4.
48. HUNT WE, HESS RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. *J Neurosurg* 1968;28(1):14-20.
49. Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. *J Neurosurg* 1988;68(6):985-6.
50. KASSELL NF, TORNER JC, HALEY EC Jr, JANE JA, ADAMS HP, KONGABLE GL. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. *J Neurosurg* 1990;73(1):18-36.
51. MORGENSTERN LB, LUNA-GONZALES H, HUBER JC Jr, et al. Worst headache and subarachnoid hemorrhage: prospective, modern computed tomography and spinal fluid analysis. *Ann Emerg Med* 1998;32(3 Pt 1):297-304.
52. SAMES TA, STORROW AB, FINKELSTEIN JA, MARGOON MR. Sensitivity of new-generation computed tomography in subarachnoid hemorrhage. *Acad Emerg Med* 1996;3(1):16-20.
53. PERRY JJ, STIELL IG, SIVILOTTI ML, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. *BMJ* 2011;343:4277.
54. SIDMAN R, CONNOLLY E, LEMKE T. Subarachnoid hemorrhage diagnosis: lumbar puncture is still needed when the computed tomography scan is normal. *Acad Emerg Med* 1996;3(9):827-31.
55. van der WEE N, RINKEL GJ, HASAN D, van GIJN J. Detection of subarachnoid haemorrhage on early CT: is lumbar puncture still needed after a negative scan? *J Neurol Neurosurg Psychiatry* 1995;58(3):357-9.
56. van GIJN J, van DONGEN KJ. The time course of aneurysmal haemorrhage on computed tomograms. *Neuroradiology* 1982;23(3):153-6.
57. FISHER CM, KISTLER JP, DAVIS JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. *Neurosurgery* 1980;6(1):1-9.
58. FIEBACH JB, SCHELLINGER PD, GELETNEKY K, WILDE P, MEYER M, HACKE W, SARTOR K. MRI in acute subarachnoid haemorrhage: findings with a standardised stroke protocol. *Neuroradiology* 2004;46:44-8.
59. KIDWELL C, WINTERMARK M. Imaging of intracranial haemorrhage. *Lancet Neurol* 2008;7:256-67.
60. SHIMODA M, HOSHIKAWA K, SHIRAMIZU H, ODA S, MATSUMAE M. Problems with diagnosis by fluid-attenuated inversion recovery magnetic resonance imaging in patients with acute aneurysmal subarachnoid hemorrhage. *Neurol Med Chir (Tokyo)* 2010;50:530-7.
61. DONMEZ H, SERIFOV E, KAHRIMAN G, MAVILI E, DURAK AC, MENKÜ A. Comparison of 16-row multislice CT angiography with conventional angiography for detection and evaluation of intracranial aneurysms. *Eur J Radiol* 2011;80:455-61.
62. MCKINNEY AM, PALMER CS, TRUWIT CL, KARAGULLE A, TEKSAM M. Detection of aneurysms by 64-section multidetector CT angiography in patients acutely suspected of having an intracranial aneurysm and comparison with digital subtraction and 3D rotational angiography. *AJNR Am J Neuroradiol* 2008;29:594-602.
63. BRINJIKJI W, KALLMES DF, WHITE JB, LANZINO G, MORRIS JM, CLOFT HJ. Inter- and intraobserver agreement in CT characterization of nonaneurysmal perimesencephalic subarachnoid hemorrhage. *AJNR Am J Neuroradiol* 2010;31:1103-5.
64. AGID R, ANDERSSON T, ALMQVIST H, WILLINSKY RA, LEE SK, terBRUGGE KG, FARB RI, SÖDERMAN M. Negative CT angiography findings in patients with spontaneous subarachnoid hemorrhage: when is digital subtraction angiography still needed? *AJNR Am J Neuroradiol* 2010;31:696-705.
65. FIFI JT, MEYERS PM, LAVINE SD, COX V, SILVERBERG L, MANGLA S, PILE-SPPELLMAN J. Complications of modern diagnostic cerebral angiography in an academic medical center. *J Vasc Interv Radiol* 2009;20:442-7.
66. BARDACH NS, OLSON SJ, ELKINS JS, SMITH WS, LAWTON MT, JOHNSTON SC. Regionalization of treatment for subarachnoid hemorrhage: a cost-utility analysis. *Circulation* 2004;109:2207-12.

67. SUAREZ JI, ZAIDAT OO, SURI MF, et al. Length of stay and mortality in neurocritically ill patients: impact of a specialized neurocritical care team. *Crit Care Med* 2004;32:2311-7.
68. BERMAN MF, SOLOMON RA, MAYER SA, JOHNSTON SC, YUNG PP. Impact of hospital-related factors on outcome after treatment of cerebral aneurysms. *Stroke* 2003;34(9):2200-7.
69. CROSS DT 3rd, TIRSCHWELL DL, CLARK MA, et al. Mortality rates after subarachnoid hemorrhage: variations according to hospital case volume in 18 states. *J Neurosurg* 2003;99(5):810-17.
70. COWAN JA Jr, DIMICK JB, WAINESS RM, UPCHURCH GR Jr, THOMPSON BG. Outcomes after cerebral aneurysm clip occlusion in the United States: the need for evidence-based hospital referral. *J Neurosurg* 2003;99(6):947-52.
71. FRONTERA JA, FERNANDEZ A, SCHMIDT JM, CLAASSEN J, WARTENBERG KE, BADJATIA N, PARRA A, CONNOLLY ES, MAYER SA. Impact of nosocomial infectious complications after subarachnoid hemorrhage. *Neurosurgery* 2008;62:80-7.
72. MEHTA V, HOLNESS RO, CONNOLLY K, WALLING S, HALL R. Acute hydrocephalus following aneurysmal subarachnoid hemorrhage. *Can J Neurol Sci* 1996;23(1):40-5.
73. SHEEHAN JP, POLIN RS, SHEEHAN JM, BASKAYA MK, KASSELL NF. Factors associated with hydrocephalus after aneurysmal subarachnoid hemorrhage. *Neurosurgery* 1999;45(5):1120-7.
74. SUAREZ-RIVERA O. Acute hydrocephalus after subarachnoid hemorrhage. *Surg Neurol* 1998;49(5):563-5.
75. HASAN D, VERMEULEN M, WIJDICKS EF, HIJDRA A, van GIJN J. Management problems in acute hydrocephalus after subarachnoid hemorrhage. *Stroke* 1989;20(6):747-53.
76. GÜRESIR E, SCHUSS P, VATTER H, RAABE A, SEIFERT V, BECK J. Decompressive craniectomy in subarachnoid hemorrhage. *Neurosurg Focus* 2009;26(6):E4.
77. WIJDICKS EF, VERMEULEN M, MURRAY GD, HIJDRA A, van GIJN J. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. *Clin Neurol Neurosurg* 1990;92:111-7.
78. LANZINO G, KASSELL NF, GERMANSON T, TRUSKOWSKI L, ALVES W. Plasma glucose levels and outcome after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 1993;79:885-91.
79. JUVELA S, SIIRONEN J, KUHMENONEN J. Hyperglycemia, excess weight, and history of hypertension as risk factors for poor outcome and cerebral infarction after aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2005;102:998-1003.
80. DORHOUT MEES SM, van DIJK GW, ALGRA A, KEMPINK DR, RINKEL GJ. Glucose levels and outcome after subarachnoid hemorrhage. *Neurology* 2003;61:1132-3.
81. WARTENBERG KE, SCHMIDT JM, CLAASSEN J, TEMES RE, FRONTERA JA, OSTAPKOVICH N, PARRA A, CONNOLLY ES, MAYER SA. Impact of medical complications on outcome after subarachnoid hemorrhage. *Crit Care Med* 2006;34:617-23.
82. POUSSA K, ILVESKERO S, HERNESNIEMI J, LASILA R. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. *J Neurosurg* 2003;99:953-9.
83. JUVELA S, SIIRONEN J, VARIS J, POUSSA K, PORRAS M. Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2005;102:194-201.
84. DICKINSON LD, MILLER LD, PATEL CP, GUPTA SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. *Neurosurgery* 1998;43:1074-81.
85. BLACK PM, BAKER MF, SNOOK CP. Experience with external pneumatic calf compression in neurology and neurosurgery. *Neurosurgery* 1986;18:440-4.
86. NACCARATO M, CHIODO GRANDI F, DENNIS M, SANDERCOCK PA. Physical methods for preventing deep vein thrombosis in stroke. *Cochrane Database Syst Rev* 2010:CD001922.
87. LACUT K, BRESSOLLETTE L, Le GAL G, ETIENNE E, De TINTENIAC A, RENAULT A, ROUHART F, BESSON G, GARCIA JF, MOTTIER D, OGER E. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. *Neurology* 2005;65:865-9.
88. BUTZKUEVEN H, EVANS AH, PITMAN A, LEOPOLD C, JOLLEY DJ, KAYE AH, KILPATRICK CJ, DAVIS SM. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. *Neurology* 2000;55:1315-20.
89. LIN CL, DUMONT AS, LIEU AS, YEN CP, HWANG SL, KWAN AL, KASSELL NF, HOWNG SL. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2003;99:978-85.
90. CLAASSEN J, JETTE N, CHUM F, GREEN R, SCHMIDT M, CHOI H, JIRSCH J, FRONTERA JA, CONNOLLY ES, EMERSON RG, MAYER SA, HIRSCH LJ. Electrographic seizures and periodic discharges after intracerebral hemorrhage. *Neurology* 2007;69:1356-65.
91. DENNIS LJ, CLAASSEN J, HIRSCH LJ, EMERSON RG, CONNOLLY ES, MAYER SA. Nonconvulsive status epilepticus after subarachnoid hemorrhage. *Neurosurgery* 2002;51:1136-43.
92. ROSENGART AJ, HUO JD, TOLENTINO J, NOVAKOVIC RL, FRANK JI, GOLDENBERG FD, MACDONALD RL. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. *J Neurosurg* 2007;107:253-60.
93. WHITFIELD PC, KIRKPATRICK PJ. Timing of surgery for aneurysmal subarachnoid hemorrhage. *Cochrane Database Syst Rev* 2001;(2):CD001697. Review

94. TODD MM, HINDMAN BJ, CLARKE WR, TORNER JC. Mild intraoperative hypothermia during surgery for intracranial aneurysm. *N Engl J Med* 2005;352:135-45.
95. GUGLIELMI G, VINUELA F, DION J, DUCKWILER G. Electrothrombosis of saccular aneurysms *via* endovascular approach. Part 2: Preliminary clinical experience. *J Neurosurg* 1991;75:8-14.
96. MOLYNEUX A, KERR R, STRATTON I, *et al.* International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping *versus* endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. *Lancet* 2002;360:1267-74.
97. MOLYNEUX AJ, KERR RS, YU L-M, *et al.* International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping *versus* endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. *Lancet* 2005;366:809-17.
99. HIJDRA A, VERMEULEN M, van GIJN J, van CREVEL H. Rerupture of intracranial aneurysms: a clinicoanatomic study. *J Neurosurg* 1987;67:29-33.
99. de GANS K, NIEUWKAMP DJ, RINKEL GJ, ALGRA A. Timing of aneurysm surgery in subarachnoid hemorrhage: a systematic review of the literature. *Neurosurgery* 2002;50:336-40.
100. LAIDLAW JD, SIU KH. Poor-grade aneurysmal subarachnoid hemorrhage: outcome after treatment with urgent surgery. *Neurosurgery* 2003;53:1275-80.
101. MOLYNEUX AJ, KERR RS, BIRKS J, RAMZI N, YARNOLD J, SNEADE M, RISCHMILLER J. Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. *Lancet Neurol* 2009;8:427-33.
102. CAMPI A, RAMZI N, MOLYNEUX AJ, SUMMERS PE, KERR RS, SNEADE M, YARNOLD JA, RISCHMILLER J, BYRNE JV. Retreatment of ruptured cerebral aneurysms in patients randomized by coiling or clipping in the International Subarachnoid Aneurysm Trial (ISAT). *Stroke* 2007;38:1538-44.
103. MITCHELL P, KERR R, MENDELOW AD, MOLYNEUX A. Could late rebleeding overturn the superiority of cranial aneurysm coil embolization over clip ligation seen in the International Subarachnoid Aneurysm Trial? *J Neurosurg* 2008;108:437-42.
104. O'KELLY CJ, KULKARNI AV, AUSTIN PC, WALLACE MC, URBACH D. The impact of therapeutic modality on outcomes following repair of ruptured intracranial aneurysms: an administrative data analysis. *Clinical article. J Neurosurg* 2010;113:795-801.
105. PIOTIN M, BLANC R, SPELLE L, MOUNAYER C, PIANTINO R, SCHMIDT PJ, MORET J. Stent-assisted coiling of intracranial aneurysms: clinical and angiographic results in 216 consecutive aneurysms. *Stroke* 2010;41:110-5.

Sažetak

OPĆE PREPORUKE ZA LIJEČENJE ANEURIZMATSKOG SUBARAHNOIDNOG KRVARENJA

Subarahnoidno krvarenje je hitno neurološko stanje s visokom stopom smrtnosti i komplikacija. Preporuke su temeljene na dostupnoj literaturi, rezultatima velikih međunarodnih kliničkih ispitivanja i kolektivnom iskustvu autora, a prihvaćene od strane Hrvatskoga društva za neurovaskularne poremećaje, Hrvatskoga društva za neurologiju uključivo i Sekciju za intenzivnu neurologiju, Hrvatskoga društva za neurokirurgiju, Hrvatskoga društva za zbrinjavanje otežanog dišnog puta i Hrvatskoga liječničkog zbora. Cilj ovih preporuka je pomoć liječnicima u donošenju odgovarajućih odluka u dijagnostici i liječenju bolesnika sa subarahnoidnim krvarenjem.

Ključne riječi: *Subarahnoidno krvarenje – dijagnoza; Aneurizma – dijagnoza; Subarahnoidno krvarenje – liječenje; Aneurizma – liječenje; Praktična smjernica*